

**ANTIBODY-DRUG CONJUGATES COMPRISING HUMANIZED ANTIBODIES
TARGETING UROKINASE TYPE PLASMINOGEN ACTIVATOR RECEPTOR
ASSOCIATED PROTEIN (UPARAP)**

Field of invention

5 The present invention relates to antibodies and molecular conjugates targeting the
receptor uPARAP, in particular antibody-drug conjugates (ADCs) comprising
humanized antibodies directed against uPARAP and their use in delivery of active
agents to cells and tissues expressing uPARAP. The invention further relates to the
use of said ADCs in the treatment of diseases involving uPARAP expressing cells,
such as certain cancers.

10

Background

Urokinase-type Plasminogen Activator Receptor Associated Protein (uPARAP), also
known as CD280, Endo180 and mannose receptor C type 2, is a member of the
15 macrophage mannose receptor family of endocytic transmembrane glycoproteins.
uPARAP is a membrane protein involved in matrix turnover during tissue remodelling,
particularly the uptake and intracellular degradation of collagen. The uPARAP receptor
consists of an N-terminal cysteine-rich domain (CysR), a fibronectin type II (FN-II)
domain, and eight C-type lectin-like domains (CTLDs 1-8)

20

The receptor uPARAP is upregulated in the tumour cells of specific cancers, including
sarcomas and late-stage glioblastoma. Additionally, the receptor is most often
upregulated in stromal cells surrounding solid tumours and some literature suggests a
high expression of uPARAP in bone metastasis from prostate cancer (Caley et al.,
25 2012, J. Pathol 5: 775-783). In healthy adult individuals, the receptor displays a
restricted expression pattern (Melander et al., 2015, Int J Oncol 47: 1177-1188).

Antibody-drug conjugates (ADCs) are a class of highly potent biopharmaceutical drugs
designed as a targeted therapy, in particular for the treatment of cancer. ADCs are
30 complex molecules composed of an antibody (a whole mAb or an antibody fragment)
linked, via a stable, chemical, linker that may possess labile bonds, to an active agent,
such as a biologically active drug or cytotoxic compound. By combining the unique
targeting capabilities of antibodies with the cell-killing ability of cytotoxic drugs,
antibody-drug conjugates allow sensitive discrimination between healthy and diseased
35 tissue, based on expression of the antibody antigen. This means that, in contrast to

traditional chemotherapeutic agents, antibody-drug conjugates actively target and attack cancer cells, so that healthy cells with little or no antigen expression are less severely affected. To date, more than 10 ADCs have received market approval and several ADCs are currently in clinical trials.

5

WO 2010/111198 discloses conjugates comprising an anti-uPARAP antibody and suggests use of such conjugates in the delivery of therapeutic agents to cells that express uPARAP.

10

WO 2017/133745 discloses ADCs directed against uPARAP.

Treatment methods currently exist for most cancer types. However, in many cases with unsatisfactory efficiency or with adverse effects due to high dosing of the therapeutic agent. Thus, there is a need for more efficient treatments with increased potency.

15

Summary

Provided herein is a humanized version of the murine 9b7 antibody, and its implementation in antibody-drug conjugates (ADCs) targeting the uPARAP receptor.

20

The murine 9b7 antibody was originally described in WO 2017/133745. The antibodies and ADCs as described herein are capable of specifically targeting cells and tissues expressing uPARAP, and demonstrate enhanced efficacy compared to ADCs comprising the murine 9b7 antibody as well as enhanced efficacy compared to other humanized versions of the murine 9b7 antibody.

25

In particular, the present disclosure relates to an antibody which binds to uPARAP comprising:

- a. an immunoglobulin light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 3; and/or
- 30 b. an immunoglobulin heavy chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 6.

Further, the present disclosure relates to an antibody-drug conjugate (ADC) comprising:

- 35 a. the antibody as defined herein above,

- b. an active agent, and
- c. optionally a linker which links a) to b).

5 Furthermore, the present disclosure relates to a method for treatment of a disease characterised by cells expressing uPARAP, said method comprising administering to a subject the antibody as defined herein above, the ADCs as defined herein above, or a pharmaceutical composition comprising the antibody or the ADCs as defined herein above.

10 Further aspects of the present disclosure are a polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO: 2 and/or SEQ ID NO: 5; an isolated polynucleotide encoding the amino acid sequence as defined herein; a vector comprising the polynucleotide as defined above; and a host cell comprising the polynucleotide as defined above and/or the vector as defined above.

15 An even further aspect of the present disclosure is a kit comprising the antibody as defined above, the ADCs as defined above, or a pharmaceutical composition comprising the antibody or the ADCs as defined herein above, optionally further comprising means for administering the antibody or antibody-drug conjugate to a
20 subject and/or instructions for use

Description of Drawings

25 **Figure 1:** *In vitro* cell viability assays of U937 cancer cell lines exposed to MMAE-based ADCs comprising either the LC0HC0 antibody (comprising the variable domains of the original murine 9b7 antibody fused to human IgG constant regions), or the humanized LC4HC3 antibody. But for the antibody, the two ADCs are identical and were produced by identical methods. Cells were incubated for 96 hours, before being analyzed by colorimetric viability assay. The assay for the U937 cell line shows that
30 ADCs based on LC4HC3 have a significantly greater reduction in overall cell viability compared to the LC0HC0 ADCs.

Figure 2: Internalization of humanized antibodies LC4HC3 and LC3HC3 in SAOS-2 osteosarcoma cells. Detailed protocols are presented in Example 2. The data shows

that LC4HC3 is internalized not only faster than LC3HC3 but also to a greater extent in SAOS-2 osteosarcoma cells.

Figure 3: *In vivo* efficacy of Vedotin-type ADCs based on LC4HC3 (LC4HC3-vc-MMAE, Fig. 3a) and LC3HC3 (LC3HC3-vc-MMAE, Fig. 3b). CB17 mice were inoculated with U937 cells to induce tumor growth. Tumor size was closely monitored and treatment initiated once a size of approximately 80-150 mm³ was reached. But for the antibody, the two ADCs are identical and were produced by identical methods. Each line in Figs. 3a and 3b represents tumor size in a mouse administered a 4mg/kg dose of the referenced ADC for 7 days, twice daily. The data shows that ADCs based on humanized 9b7 antibody LC4HC3 are superior antitumor agents compared to ADCs based on a different humanized 9b7 antibody, LC3HC3.

Detailed description

The antibodies of the present disclosure are internalised upon binding to uPARAP receptors at the cell surface, thus allowing for intracellular actions of the active agent of the antibody-drug conjugate complex.

Provided herein are humanised versions of the murine 9b7 antibody, which bind to the uPARAP receptor.

Anti-uPARAP humanised antibodies

Methods of generating antibodies are well known in the art. For example, antibodies may be generated via any one of several methods which employ induction of *in vivo* production of antibody molecules, screening of immunoglobulin libraries, or generation of monoclonal antibody molecules by cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the Epstein-Barr virus (EBV)-hybridoma technique.

Humanised antibodies are generally preferred in medicines intended for humans and methods for humanising antibodies are well known in the art. Although humanisation techniques are known, it can be a challenge to achieve humanised antibodies that retain the binding properties of the initial antibody and even more challenging to achieve

humanised antibodies with improved characteristics, such as improved ligand affinity and efficacy compared to the initial antibody.

5 The inventors herein provide an improved anti-uPARAP antibody, which is a humanised version of the 9b7 murine antibody and which displays improved ligand affinity and efficacy compared to the 9b7 murine antibody as well as improved internalization and *in vivo* efficacy compared to other humanized versions of the 9b7 antibody.

10 The anti-uPARAP antibody of the present disclosure may be of any immunoglobulin class including IgG, IgM, IgD, IgE, IgA, and any subclass thereof. IgG subclasses are also well known to those in the art and include but are not limited to human IgG1, IgG2, IgG3 and IgG4. In one embodiment the antibody is an IgG monoclonal antibody. In one embodiment the antibody is IgG1 κ .

15 The anti-uPARAP antibody of the present disclosure is a humanised 9b7 antibody, which binds to the uPARAP receptor, more specifically, the humanized 9b7 antibody disclosed herein binds at least to the fibronectin type II (FN-II) domain of the uPARAP receptor.

20 The humanized 9b7 antibody, also referred to herein as 980.2 LC4HC3, comprises a light chain variable region of amino acids comprising SEQ ID NO: 3, which is the variable region of LC4, and a heavy chain variable region of amino acids comprising SEQ ID NO:6, which is the variable region of HC3.

25 The humanized 9b7 antibody, also referred to herein as 980.2 LC4HC3, may comprise a light chain of amino acids comprising or consisting of SEQ ID NO: 1, which is LC4, and a heavy chain of amino acids comprising or consisting of SEQ ID NO:4, which is HC3.

30 In one embodiment of the present disclosure, the anti-uPARAP antibody as defined herein comprises:

- 35
- a. an immunoglobulin light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 3; and/or
 - b. an immunoglobulin heavy chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 6.

In one embodiment of the present disclosure, the antibody which binds to uPARAP as defined herein comprises:

- 5 a. an immunoglobulin light chain comprising the amino acid sequence of SEQ ID NO: 1 (LC4); and/or
- b. an immunoglobulin heavy chain comprising the amino acid sequence of SEQ ID NO: 4 (HC3).

10 In one embodiment of the present disclosure, the antibody which binds to uPARAP as defined herein comprises:

- a. an immunoglobulin light chain consisting of the amino acid sequence of SEQ ID NO: 1 (LC4); and
- b. an immunoglobulin heavy chain consisting of the amino acid sequence of SEQ ID NO: 4 (HC3).

15

Polypeptides, polynucleotides, vectors and host cells

One embodiment of the present disclosure is a polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO: 2 and/or SEQ ID NO: 5. SEQ ID NO: 2 and
20 SEQ ID NO: 5 correspond to SEQ ID NO: 1 and SEQ ID NO: 4, respectively, but further have a N-terminal signal peptide for expression purposes.

One embodiment of the present disclosure is an isolated polynucleotide encoding any of the polypeptides disclosed herein, i.e. an isolated polynucleotide which encodes the
25 amino acid sequence of any one of SEQ ID NOs: 1, 2, 3, 4, 5 and/or 6.

In one embodiment, the polynucleotide comprises SEQ ID NO: 11 and/or SEQ ID NO: 12, encoding SEQ ID NO: 2 and SEQ ID NO: 5, respectively.

30 In one embodiment the polypeptide comprises or consists of the amino acid sequence of SEQ ID NO: 2, optionally wherein the polypeptide further comprises the amino acid sequence of SEQ ID NO: 5 .

In one embodiment this disclosure provides an isolated polynucleotide which encodes the amino acid sequence of any one of SEQ ID NOs: 1, 2, or 3, optionally wherein the polynucleotide further encodes the amino acid sequence of any one of 4, 5 or 6.

- 5 In one embodiment this disclosure provides an isolated polynucleotide comprising SEQ ID NO: 11, optionally wherein the polynucleotide further comprises SEQ ID NO: 12.

In one embodiment the polypeptide is an isolated polypeptide.

- 10 One embodiment of the present disclosure is a vector, such as an expression vector, comprising the polynucleotide as defined herein.

In one embodiment of the present disclosure, the vector is a mammalian expression vector.

15

In one embodiment of the present disclosure, the vector is a plasmid vector, such as a plasmid vector selected from pD2610-v13 (ATUM), pSV and the pCMV series of plasmid vectors.

- 20 In one embodiment of the present disclosure, the vector is a viral vector, such as a viral vector selected from the group consisting of adenoviral vectors, lentiviral vectors, adeno-associated viral vectors, herpesviral vectors, vaccinia viral vectors, poxviral vectors, baculoviral vectors and oncolytic viral vectors.

- 25 A further embodiment of the present disclosure is a host cell comprising the polynucleotide and/or the vector as defined herein.

- In one embodiment of the present disclosure, the host cell comprising the polynucleotide and/or the vector as described herein is selected from the group consisting of CHO (Chinese hamster ovary) cells, COS (CV-1 (simian) in Origin, and carrying the SV40 genetic material) cells, HEK (Human embryonic kidney) cells and HeLa (Henrietta Lacks) cells.
- 30

In one embodiment, the host cell is CHO.

35

In one embodiment the host cell is a recombinant host cell.

Antibody-drug conjugates (ADCs) comprising anti-uPARAP humanised antibodies

5 The data of the inventors surprisingly shows that ADCs based on LC4HC3 (humanized 9b7 antibody) result in a significantly greater reduction in overall cell viability compared to the ADCs based LC0HC0 (having variable domains of the 9b7 murine antibody fused to human IgG constant regions). ADCs based on LC4HC3 also exhibit improved internalization and *in vivo* efficacy compared to ADCs based on LC3HC3 (another
10 humanized 9b7 antibody).

One particularly preferred embodiment of the present disclosure is an antibody-drug conjugate (ADC) comprising:

- 15 a. the antibody as defined herein,
 b. an active agent, and
 c. optionally a linker which links a) to b).

In one embodiment of the present disclosure, the antibody-drug conjugate (ADC) as defined herein comprises:

- 20 a. the antibody as defined herein, comprising:
 i) an immunoglobulin light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 3; and/or
 ii) an immunoglobulin heavy chain variable region
25 comprising or consisting of the amino acid sequence of SEQ ID NO: 6
 b. an active agent, and
 c. optionally a linker which links a) to b).

30 In one embodiment of the present disclosure, the antibody-drug conjugate (ADC) as defined herein comprises:

- a. the antibody as defined herein, comprising:
 i) an immunoglobulin light chain comprising or consisting of the amino acid sequence of SEQ ID NO: 1; and/or

- ii) an immunoglobulin heavy chain comprising or consisting of the amino acid sequence of SEQ ID NO: 4
- b. an active agent, and
- c. optionally a linker which links a) to b).

5

In one embodiment of the present disclosure, the antibody-drug conjugate (ADC) as defined herein comprises:

- a. the antibody as defined herein, comprising:
 - i) an immunoglobulin light chain consisting of the amino acid sequence of SEQ ID NO: 1; and
 - ii) an immunoglobulin heavy chain consisting of the amino acid sequence of SEQ ID NO: 4
- b. an active agent, and
- c. optionally a linker which links a) to b).

10
15

Active agent

The ADCs of the present disclosure comprise an active agent, e.g. a drug, which can be delivered intracellularly to cells expressing uPARAP. The active agent may e.g. be a therapeutic agent, a radioisotope or a detectable label. In a preferred embodiment the active agent is a therapeutic agent.

In one embodiment, the active agent may be or comprise a radioisotope. The radioisotope may serve as a radiation emitter either for treatment of affected tissues or for diagnostic purposes. In one embodiment, the radioisotope may consist of or comprise ^{60}Co , ^{89}Sr , ^{90}Y , $^{99\text{m}}\text{Tc}$, ^{131}I , ^{137}Cs , ^{153}Sm , or ^{223}Rd . In one embodiment of the present disclosure, the radioisotope may be in combination with a chelator such as DOTA or EDTA or others which are well known in the art.

In one embodiment the active agent is a therapeutic agent. Classes of therapeutic agents include DNA crosslinking agents, DNA alkylating agents, DNA strand scission agents, anthracyclines, antimetabolites, anti-microtubule/anti-mitotic agents, histone deacetylase inhibitors, kinase inhibitors, metabolism inhibitors, peptide antibiotics, immune checkpoint inhibitors, platinum-based antineoplastics, topoisomerase

inhibitors, DNA or RNA polymerase inhibitors, nucleotide based agents, and cytotoxic antibiotics.

5 In a preferred embodiment the active agent is a cytotoxic agent allowing for efficient killing of the cells expressing uPARAP.

In one embodiment the active agent is a chemotherapeutic agent.

10 In one embodiment, the active agent is a DNA-crosslinking agent, such as a DNA crosslinking agent selected from cisplatin or a derivative of cisplatin such as carboplatin or oxaliplatin, mitomycin C (MMC), pyrrolobenzodiazepine, and dimeric pyrrolobenzodiazepine derivatives such as SGD-1882 or a derivative of any of these.

15 In one embodiment of the present disclosure, the active agent is a DNA alkylating agent, such as a DNA alkylating agent selected from nitrogen mustards such as tris(2-chloroethyl)amine, pyridinobenzodiazepines or a pyridinobenzodiazepine derivative, indolinobenzodiazepine dimers, and Duocarmycin SA or a derivative of any of these.

20 In one embodiment, the active agent is a DNA strand scission agent, such as a DNA strand scission agent selected from calicheamicin and hamilttrone or a derivative of any of these.

25 In one embodiment the active agent is an anthracycline, such as an anthracycline selected from Daunorubicin, doxorubicin, epirubicin, idarubicin, and PNU-159682 or a derivative of any of these.

30 In one embodiment the active agent is an antimetabolite, such as an antimetabolite selected from folic acid antagonists such as methotrexate, purine antimetabolites such as 6-mercaptopurine or 6-thioguanine or fludarabine phosphate or pentostatin or cladribine, and pyrimidine antimetabolites such as 5-fluorouracil or 5-fluorodeoxyuridine or cytarabine or gemcitabine, or a derivative of any of these.

35 In one embodiment the active agent is an anti-mitotic agent, such as selected from the group consisting of derivatives of auristatin or dolastatin such as monomethyl auristatin E (MMAE), monomethyl auristatin F (MMAF) and more, a taxane such as Paclitaxel or

Docetaxel and more, a vinca alkaloid such as Vinblastine, Vincristine, Vindesine or Vinorelbine and more, a maytansinoid, Colchicine, and Podophyllotoxin or a derivative of any of these.

- 5 In one embodiment, the active agent is monomethyl auristatin E (MMAE) or a derivative thereof.

Because of its high toxicity, MMAE, which inhibits cell division by blocking the polymerization of tubulin, cannot be used as a single-agent chemotherapeutic drug.

- 10 However, the combination of MMAE linked to an anti-CD30 monoclonal antibody (Brentuximab Vedotin, trade name Adcetris™) has been proven to be stable in extracellular fluid, cleavable by cathepsin and safe for therapy.

- 15 In one embodiment, the active agent is a histone deacetylase inhibitor, such as a histone deacetylase inhibitor selected from trichostatin A, vorinostat, belinostat, panabostat, givinostat, resminostat, abexinostat, quisinostat, rocilinostat, practinostat, CHR-3996, valproic acid, butyric acid, phenylbutyric acid, entinostat, tacedinaline, 4SC202, mocetinostat, romidepsin, nicotinamide, sirtinol, cambinol, and EX-527 or a derivative of any of these.

- 20 In one embodiment, the active agent is a kinase inhibitor, such as a kinase inhibitor selected from genistein, lavendustin C, PP1-AG1872, PP2-AG1879, SU6656, CGP77675, PD166285, imatinib, erlotinib, gefitinib, lavendustin A, cetuximab, UCS15A, herbimycin A, and radicicol or a derivative of any of these.

- 25 In one embodiment, the active agent is a metabolism inhibitor, such as an NAMPT inhibitor. Examples of NAMPT inhibitors include APO866, GMX-1777, GMX-1778 ATG-019, and OT-82 or a derivative of any of these.

- 30 In one embodiment, the active agent is an immune checkpoint inhibitor, such as a PD-1 inhibitor or a PD-L1 inhibitor. Examples of PD-1 inhibitors include Pembrolizumab, Nivolumab, Cemiplimab, JTX-4014, Spartalizumab, Camrelizumab, Sintilimab, Tislelizumab, Toripalimab, Dostarlimab, AMP-224 and AMP-514. Examples of PD-L1 inhibitors include Atezolizumab, Avelumab, Durvalumab, KN035, CK-301, AUNP12, 35 CA-170 and BMS-986189 or a derivative of any of these.

In one embodiment, the active agent is a platinum-based antineoplastic, such as a platinum-based antineoplastic selected from lipoplatin, cisplatin, carboplatin, oxaliplatin, nedaplatin, picoplatin, phenanthriplatin, satraplatin, and triplatin tetranitrate or a derivative of any of these.

In one embodiment, the active agent is a topoisomerase inhibitor, such as a topoisomerase inhibitor selected from camptothecin or derivatives thereof such as topotecan, belotecan, lurtotecan, irinotecan, SN-38, exatecan, and Dxd or a derivative of any of these.

In one embodiment, the active agent is a DNA- or RNA-polymerase inhibitor, such as a polymerase inhibitor selected from amanitin or alpha-amanitin or derivatives thereof, actinomycin D, and aphidicolin or a derivative of any of these.

In one embodiment, the active agent is a nucleotide-based agent, such as an RNA- or DNA-oligonucleotide, such as an siRNA or a miRNA.

There may be one or more units of drug per antibody molecule. The ratio between the number of drug molecules per antibody is denoted the drug-to-antibody ratio (DAR). In one embodiment, the DAR is between 1 and 10, such as between 2 and 8, for example between 2 and 6, such as 2 or 4.

Linker

A stable link between the antibody and the active agent is an important aspect of ADC technology. Linkers may e.g. be based on chemical motifs including disulfides, hydrazones or peptides (cleavable), or thioethers (noncleavable), and control the distribution and delivery of the cytotoxic agent to the target cell. Cleavable and noncleavable types of linkers have been proven to be safe in preclinical and clinical trials. For example, Brentuximab Vedotin includes an enzyme-sensitive cleavable linker that delivers the potent and highly toxic antimicrotubule agent monomethyl auristatin E (MMAE), a synthetic antineoplastic agent, to cells.

Trastuzumab Emtansine, another approved ADC, is a combination of the microtubule-formation inhibitor mertansine (DM-1), a derivative of the Maytansine, and antibody Trastuzumab (Herceptin™, Genentech/Roche), attached by a stable, non-cleavable linker.

5

The type of linker, cleavable or non-cleavable, lends specific properties to the delivered drug. For example, cleavable linkers can e.g. be cleaved by enzymes in the target cell, leading to efficient intracellular release of the active agent, for example a cytotoxic agent. In contrast, an ADC containing a non-cleavable linker has no mechanism for drug release, and must rely on mechanisms such as degradation of the targeting antibody, for drug release. Furthermore, as is appreciated by those skilled in the art, the linker composition may influence critical factors such as solubility and pharmacokinetic properties of the ADC as a whole.

For both types of linker, drug release is crucial for obtaining a cellular effect. Drugs which are able to freely diffuse across cell membranes may escape from the targeted cell and, in a process called “bystander killing,” also attack neighbouring cells, such as cancer cells in the vicinity of the uPARAP expressing target cell.

In a preferred embodiment of the present disclosure, the ADC targeting uPARAP as disclosed herein comprises a linker that links the antibody to the active agent.

In one embodiment of the present disclosure, the linker may be cleavable or non-cleavable.

25

Cleavable groups include a disulfide bond, an amide bond, a substituted amide bond in the form of a peptide bond, a thioamide, bond, an ester bond, a thioester bond, a vicinal diol bond, or a hemiacetal. These, or other cleavable bonds, may include enzymatically-cleavable bonds, such as peptide bonds (cleaved by peptidases), phosphate bonds (cleaved by phosphatases), nucleic acid bonds (cleaved by endonucleases), and sugar bonds (cleaved by glycosidases).

In a further embodiment of the present disclosure, the linker is a cleavable linker allowing for intracellular release of the active agent inside the target cells.

35

In a further embodiment the linker is a peptide linker. The choice of peptide sequence is critical to the success of the conjugate. In some embodiments the linker is stable to serum proteases, yet is cleaved by lysosomal enzymes in the target cell.

- 5 In a further embodiment the linker is an enzyme-cleavable peptide-containing linker, such as a cathepsin cleavable peptide-containing linker. Cathepsin can be one of several cathepsin types, being one of a group of lysosomal proteases.

- 10 In a further embodiment of the present disclosure, the linker comprises or consists of a dipeptide, such as valine-citrulline (VC) or valine-alanine (VA).

- 15 In one embodiment the linker comprises or consists of a dipeptide, such as valine-citrulline (VC) or valine-alanine (VA), which may be further connected through an amide linkage to other structural elements. Valine-citrulline-based linkers, in which the citrulline carboxyl function is modified to a substituted amide, can be cleaved by lysosomal cathepsins, whereas valine-alanine-based linkers, in which the alanine carboxyl function is modified to a substituted amide, can be cleaved by other lysosomal proteases, including other cathepsins.

- 20 In a further embodiment of the present disclosure, the antibody-drug conjugate as defined herein further comprises a spacer, such as a spacer comprising p-aminobenzoic acid (PAB), p-aminobenzylcarbamate (PABC), p-aminobenzoyloxycabonyl, or polyethylenglycol (PEG).

- 25 In one embodiment of the present disclosure, the antibody-drug conjugate as defined herein comprises p-aminobenzylcarbamate (PABC).

- 30 In a further embodiment of the present disclosure, the antibody-drug conjugate as defined herein further comprises an attachment group, such as an attachment group comprising or consisting of maleimide and caproic acid (MC), N-hydroxysuccinimide, reactive attachment groups directed to modified or unmodified protein-bound carbohydrate, peptide sequences that are required for enzymatic reactions, azides or alkynes or being derived from these by reaction with the antibody or a chemically or enzymatically generated derivative thereof.

35

In one embodiment of the present disclosure, the ADC of the present disclosure further comprises an attachment entity. The attachment entity may for example connect the antibody and the cleavable linker, where the attachment entity is the reaction product between an antibody amino acid side chain and a reactive attachment group in the linker precursor. In one embodiment, this reactive attachment group comprises or consists of maleimide and caproic acid (MC), where maleimide reacts preferably with cysteine thiols during coupling. In other embodiments, the attachment group comprises or consists of N-hydroxysuccinimide, reactive attachment groups directed to modified or unmodified protein-bound carbohydrate, peptide sequences that are required for enzymatic reactions, azides or alkynes or being derived from these by reaction with the antibody or a chemically or enzymatically generated derivative thereof.

In one embodiment of the present disclosure, the ADC comprises an antibody targeting uPARAP as defined herein, and the linker-drug complex Vedotin. Vedotin is a linker-drug complex comprising the cytotoxic agent MMAE, a spacer (p-aminobenzoic acid), a cathepsin-cleavable linker (Valine-citrulline dipeptide) and an attachment group consisting of caproic acid and maleimide. Vedotin is MC-VC-PAB-MMAE.

In one embodiment, the ADC of the present disclosure targeting uPARAP comprises the antibody as defined herein, and a linker-spacer-toxin unit being VC-PAB-MMAF.

In one embodiment, the ADC of the present disclosure targeting uPARAP comprises the antibody as defined herein, and a linker-spacer-toxin unit being VC-PABC-MMAF.

In one embodiment, the ADC of the present disclosure targeting uPARAP comprises or consists of:

- a. the antibody as defined herein, comprising:
 - i) an immunoglobulin light chain consisting of the amino acid sequence of SEQ ID NO: 1; and
 - ii) an immunoglobulin heavy chain consisting of the amino acid sequence of SEQ ID NO: 4.
- b. a VC linker,
- c. an MC attachment group,
- d. a PAB or a PABC spacer, and
- e. MMAE as active agent.

In one embodiment, the ADC of the present disclosure targeting uPARAP comprises or consists of:

a. the antibody as defined herein, comprising:

- 5 i) an immunoglobulin light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 3; and/or
 ii) an immunoglobulin heavy chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 6,

b. a VC linker,

10 c. an MC attachment group,

d. a PAB or a PABC spacer, and

e. MMAE as active agent.

Therapeutic use

15

The ADCs directed against uPARAP as described herein are useful for the delivery of active agents, such as therapeutic or cytotoxic agents to cells expressing uPARAP and similar proteins and thus for the treatment of a range of diseases and disorders characterized by either expression or overexpression of said proteins.

20

Thus, one embodiment of the present disclosure is the antibody or the antibody-drug conjugate as defined herein for use as a medicament.

25 One embodiment of the present disclosure is a pharmaceutical composition comprising an effective amount of the antibody or the antibody-drug conjugate as defined herein, and a pharmaceutically acceptable buffer, diluent, carrier, adjuvant or excipient.

30 A 'therapeutically effective amount', or 'effective amount', or 'therapeutically effective', as used herein, refers to that amount which provides a therapeutic effect for a given condition and administration regimen. This is a predetermined quantity of active material calculated to produce a desired therapeutic effect in association with the required additive and diluent, *i.e.* a carrier or administration vehicle. Further, it is intended to mean an amount sufficient to reduce, and most preferably prevent, a clinically significant deficit in the activity, function and response of the host. Alternatively, a therapeutically effective
35 amount is sufficient to cause an improvement in a clinically significant condition in a host.

As is appreciated by those skilled in the art, the amount of a compound may vary depending on its specific activity. Suitable dosage amounts may contain a predetermined quantity of active composition calculated to produce the desired therapeutic effect in association with the required diluent.

5

The ADCs of the present disclosure may be formulated into any type of pharmaceutical composition known in the art to be suitable for the delivery thereof.

10

The pharmaceutical compositions may be prepared in a manner known in the art that is sufficiently storage stable and suitable for administration to humans and/or animals. For example, the pharmaceutical compositions may be lyophilised, e.g. through freeze drying, spray drying, spray cooling, or through use of particle formation from supercritical particle formation.

15

By "pharmaceutically acceptable" we mean a non-toxic material that does not decrease the effectiveness of the ADC. Such pharmaceutically acceptable buffers, carriers or excipients are well-known in the art (see Remington's Pharmaceutical Sciences, 18th edition, A.R. Gennaro, Ed., Mack Publishing Company (1990) and handbook of Pharmaceutical Excipients, 3rd edition, A. Kibbe, Ed., Pharmaceutical Press (2000), the disclosures of which are incorporated herein by reference).

20

The term "buffer" is intended to mean an aqueous solution containing an acid-base mixture with the purpose of stabilising pH. Pharmaceutically acceptable buffers are well known in the art.

25

The term "diluent" is intended to mean an aqueous or non-aqueous solution with the purpose of diluting the agent in the pharmaceutical preparation.

30

The term "adjuvant" is intended to mean any compound added to the formulation to increase the biological effect of the agent of the invention. The adjuvant may be one or more of zinc, copper or silver salts with different anions, for example, but not limited to fluoride, chloride, bromide, iodide, thiocyanate, sulfite, hydroxide, phosphate, carbonate, lactate, glycolate, citrate, borate, tartrate, and acetates of different acyl composition. The adjuvant may also be cationic polymers such as cationic cellulose ethers, cationic cellulose esters, deacetylated hyaluronic acid, chitosan, cationic dendrimers, cationic

35

synthetic polymers such as poly(vinyl imidazole), and cationic polypeptides such as polyhistidine, polylysine, polyarginine, and peptides containing these amino acids.

The excipient may be one or more of carbohydrates, polymers, lipids and minerals.

5 Examples of carbohydrates include lactose, glucose, sucrose, mannitol, and cyclodextrines, which are added to the composition, e.g., for facilitating lyophilisation. Examples of polymers are starch, cellulose ethers, cellulose carboxymethylcellulose, hydroxypropylmethyl cellulose, hydroxyethyl cellulose, ethylhydroxyethyl cellulose, alginates, carageenans, hyaluronic acid and derivatives thereof, polyacrylic acid,

10 polysulphonate, polyethylenglycol/polyethylene oxide, polyethyleneoxide/polypropylene oxide copolymers, polyvinylalcohol/polyvinylacetate of different degree of hydrolysis, and polyvinylpyrrolidone, all of different molecular weight, which are added to the composition, e.g., for viscosity control, for achieving bioadhesion, or for protecting the lipid from chemical and proteolytic degradation. Examples of lipids are fatty acids,

15 phospholipids, mono-, di-, and triglycerides, ceramides, sphingolipids and glycolipids, all of different acyl chain length and saturation, egg lecithin, soy lecithin, hydrogenated egg and soy lecithin, which are added to the composition for reasons similar to those for polymers. Examples of minerals are talc, magnesium oxide, zinc oxide and titanium oxide, which are added to the composition to obtain benefits such as reduction of liquid

20 accumulation or advantageous pigment properties.

Another embodiment of the present disclosure is a method for treatment of a disease characterised by cells in a subject expressing uPARAP, said method comprising administering to the subject the antibody or the antibody-drug conjugate as defined

25 herein.

The expression and role of uPARAP in cancer has been investigated by several research groups; cf. review by Melander et al (Melander et al., 2015, Int J Oncol 47: 1177-1188) and article by Engelholm et al (Engelholm et al., 2016, J. Pathol. 238, 120-

30 133).

In one embodiment of the present disclosure, the method is the method as defined herein, wherein the disease characterised by cells expressing uPARAP is selected from cancer, a bone degradation disease such as osteoporosis, fibrosis, and

macrophage associated diseases or disorders such as atherosclerosis, arthritis, or chronic inflammation.

5 In one embodiment of the present disclosure, the method is the method as defined herein, wherein the arthritis is selected from osteoarthritis, inflammatory arthritis, rheumatoid arthritis, psoriatic arthritis, lupus, Lyme disease-induced arthritis such as Lyme arthritis, gout or pseudogout, and ankylosing spondylitis.

10 In one embodiment of the present disclosure, the method is the method as defined herein, wherein the disease is cancer.

Examples of cancers characterized by overexpression of uPARAP include, but are not limited to, sarcoma, including osteosarcoma (Engelholm et al., 2016, J Pathol 238(1): 120-33) as well as other sarcomas, glioblastoma (Huijbers et al., 2010, PLoS One 15(3):e9808), prostate cancer and bone metastases from prostate cancer (Kogianni et al., 2009, Eur J Cancer 45(4): 685-93), breast cancer and in particular "basal like" breast cancer (Wienke et al., 2007, Cancer Res 1;67(21): 10230-40), head- and neck cancer (Sulek et al., 2007, J Histochem Cytochem 55(4): 347-53), and mesothelioma (Çakılkaya et al., 2021, Int J Mol Sci 22(21): 11452).

20 In one embodiment of the present disclosure, the method is the method as defined herein, wherein the cancer is selected from sarcoma, glioblastoma, mesothelioma, colon cancer, prostate cancer, bone metastases from prostate cancer, breast cancer, head- and neck cancer, and leukaemia.

25 In one embodiment of the present disclosure, the method is the method as defined herein, wherein the cancer is leukaemia, such as acute lymphoblastic leukaemia (ALL), acute myeloid leukaemia (AML), chronic lymphocytic leukaemia (CLL), and chronic myeloid leukaemia (CML), or subtypes of these.

30 In one embodiment of the present disclosure, the method is the method as defined herein, wherein the cancer is sarcoma, such as osteosarcoma, or soft tissue sarcoma (STS), or subtypes of these.

In one embodiment of the present disclosure, the method is the method as defined herein, the soft tissue sarcoma (STS) is selected from epithelioid sarcoma, clear cell sarcoma, alveolar soft part sarcoma, extraskeletal myxoid chondrosarcoma, epithelioid hemangioendothelioma, inflammatory myofibroblastic tumor, undifferentiated
5 embryonal sarcoma, alveolar soft part sarcoma (ASPS), angiosarcoma, chondrosarcoma, dermatofibrosarcoma protuberans (DFSP), desmoid sarcoma, Ewing's sarcoma, fibrosarcoma, myxofibrosarcoma, gastrointestinal stromal tumor (GIST), non-uterine leiomyosarcoma, uterine leiomyosarcoma, liposarcoma, malignant fibro histiocytoma (MFH), malignant peripheral nerve sheath tumor (MPNST),
10 rhabdomyosarcoma, synovial sarcoma, and/or leiomyosarcoma (LMS).

In one embodiment of the present disclosure, the method is the method as defined herein, wherein the cancer is metastatic cancer

15 In one embodiment of the present disclosure, the method is the method as defined herein, wherein the cancer is a solid tumour.

In one embodiment of the present disclosure, the method is the method as defined herein, wherein the cancer is glioblastoma.

20

In one embodiment of the present disclosure, the cancer is not a solid tumour. For instance, the ADC of the present disclosure may e.g. be used for the treatment of uPARAP-expressing leukemia, for example, from the macrophage-monocyte lineage.

25 In other embodiments of the present disclosure, the disease or disorder characterised by cells expressing uPARAP is not cancer.

uPARAP is involved in bone growth and homeostasis (Madsen et al., 2013, PLoS One 5,8(8): e71261). Thus, in one embodiment the ADC of the present disclosure may be
30 used for the treatment of a disease characterized by bone degradation, wherein the bone degradation is mediated by non-malignant cells, such as osteoporosis.

Due to its role in collagen accumulation, a role for uPARAP has also been shown in fibrosis (Madsen et al., 2012, J Pathol 227(1):94-105). Thus, in one embodiment the

ADC of the present disclosure may be used for the treatment of fibrosis, for example of kidney, lung and liver.

5 In one embodiment of the present disclosure, the ADC of the present disclosure may be used for the treatment of diseases and disorders associated with macrophages, including atherosclerosis, arthritis, and chronic inflammation.

10 The ADCs of the present disclosure or pharmaceutical compositions comprising the ADCs may be administered via any suitable route known to those skilled in the art. Thus, possible routes of administration include parenteral (intravenous, subcutaneous, and intramuscular), topical, ocular, nasal, pulmonar, buccal, oral, vaginal and rectal. Also, administration from implants is possible.

15 In one preferred embodiment, the pharmaceutical compositions are administered parenterally, for example, intravenously, intracerebroventricularly, intraarticularly, intra-arterially, intraperitoneally, intrathecally, intraventricularly, intrasternally, intracranially, intramuscularly or subcutaneously, or they may be administered by infusion techniques. They are conveniently used in the form of a sterile aqueous solution which may contain other substances, for example, enough salts or glucose to make the solution isotonic with blood. The aqueous solutions should be suitably buffered if necessary.

20 In one embodiment of the present disclosure, the method is the method as defined herein, wherein the antibody-drug conjugate is administered parenterally, for example, intravenously, intracerebroventricularly, intraarticularly, intra-arterially, intraperitoneally, intrathecally, intraventricularly, intrasternally, intracranially, intramuscularly or subcutaneously, or by infusion techniques.

30 Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection

solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.

5 In one embodiment of the present disclosure, the method is the method as defined herein, wherein the antibody-drug conjugate or the antibody is administered intravenously.

10 In one embodiment of the present disclosure, the method is the method as defined herein, wherein the antibody-drug conjugate or the antibody is administered subcutaneously.

15 In one embodiment of the present disclosure, the method is the method as defined herein, wherein the antibody-drug conjugate or the antibody is administered in combination with one or more further agents, such as one or more further therapeutic agents.

20 In one embodiment of the present disclosure, the ADC or the antibody of the present disclosure is administered in conjunction with additional reagents and/or therapeutics that may increase the functional efficiency of the ADC, such as established or novel drugs that increase lysosomal membrane permeability, thereby facilitating molecular entry from the lysosome interior to the cytoplasm, or drugs that increase the permeability of the blood-brain barrier.

25 In one embodiment of the present disclosure, the ADCs or the antibodies described herein may be administered in combination with a range of anti-cancer agents, such as antimetabolites, alkylating agents, anthracyclines and other cytotoxic antibiotics, vinca alkyloids, anti-microtubule/anti-mitotic agents, histone deacetylase inhibitors, kinase inhibitors, peptide antibiotics, immune checkpoint inhibitors, platinum-based antineoplastics, etoposide, taxanes, topoisomerase inhibitors, antiproliferative
30 immunosuppressants, corticosteroids, sex hormones and hormone antagonists, cytotoxic antibiotics and other therapeutic agents.

35 Thus, in one embodiment of the present disclosure, the method is the method as defined herein, wherein the cell expressing uPARAP displays uPARAP overexpression.

In one embodiment of the present disclosure, the method is the method as defined herein, wherein the cell expressing uPARAP is a tumour cell.

5 In one embodiment of the present disclosure, the method is the method as defined herein, wherein the cell expressing uPARAP is a tumour associated cell.

Tumour associated cells include, but are not limited to, activated fibroblasts, myofibroblasts, neovasculature and infiltrating cells of the macrophage-monocyte lineage or other leukocytic cell types, as well as cells of the stromal tissue surrounding
10 the tumour.

In one embodiment of the present disclosure, the method is the method as defined herein, wherein the antibody or the antibody-drug conjugate induces cell death and/or inhibits the growth and/or proliferation of the uPARAP expressing cell.

15 In one embodiment of the present disclosure, the method is the method as defined herein, wherein the antibody or the antibody-drug conjugate induces liberation of free cytotoxin from the uPARAP expressing cells, leading to cell death and/or inhibition of the growth and/or proliferation of neighbouring cancer cells.

20 In one embodiment of the present disclosure, the method is the method as defined herein, wherein the treatment is ameliorative or curative.

A further embodiment of the present disclosure is a method for inhibiting tumour progression in a subject, comprising administering to the subject the antibody or the
25 antibody-drug conjugate or the pharmaceutical composition as defined herein to said subject.

A further embodiment of the present disclosure is a method for inhibiting, lowering or
30 eliminating metastatic capacity of a tumour in a subject, comprising administering to the subject the antibody or the antibody-drug conjugate or the pharmaceutical composition as defined herein to said subject.

An even further embodiment of the present disclosure is a kit comprising the antibody or
35 the antibody-drug conjugate or the pharmaceutical compositions as defined herein,

optionally further comprising means for administering said antibody-drug conjugate or pharmaceutical composition to a subject and/or instructions for use.

5 In one embodiment, the present disclosure relates to an antibody-drug conjugate as described herein or a pharmaceutical composition as described herein for use in the manufacture of a medicament for treatment of a disease characterised by cells expressing uPARAP, such as cancer.

10 In one embodiment, the present disclosure relates to an antibody, an antibody-drug conjugate or a pharmaceutical composition comprising said antibody or antibody-drug conjugate for use in the manufacture of a medicament for treatment of a disease characterised by cells expressing uPARAP, such as cancer, wherein said antibody or antibody-drug conjugate is or comprises an antibody comprising:

- 15
- a. an immunoglobulin light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 3; and
 - b. an immunoglobulin heavy chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 6.

20 In one embodiment, the present disclosure relates to an antibody, an antibody-drug conjugate or a pharmaceutical composition comprising said antibody or antibody-drug conjugate for use in the manufacture of a medicament for treatment of a disease characterised by cells expressing uPARAP, such as cancer, wherein said antibody or antibody-drug conjugate is or comprises an antibody comprising:

- 25
- a. an immunoglobulin light chain comprising or consisting of the amino acid sequence of SEQ ID NO: 1; and
 - b. an immunoglobulin heavy chain comprising or consisting of the amino acid sequence of SEQ ID NO: 4.

30 In one embodiment, the present disclosure relates to an antibody, an antibody-drug conjugate or a pharmaceutical composition comprising said antibody or antibody-drug conjugate for use in the manufacture of a medicament for treatment of a disease characterised by cells expressing uPARAP, such as cancer, wherein said antibody or antibody-drug conjugate is or comprises an antibody comprising:

- 35
- a. an immunoglobulin light chain consisting of the amino acid sequence of SEQ ID NO: 1; and

b. an immunoglobulin heavy chain consisting of the amino acid sequence of SEQ ID NO: 4.

Examples

5

Example 1: humanization of murine 9b7 antibody and potency of ADCs based thereon

Materials and methods

10

Humanization of the murine antibody 9b7 directed against uPARAP

Data on the murine antibody 9b7 amino acid sequence and its CDR regions are available in the published patent application WO 2017/133745.

15

Humanized variants of the 9b7 antibody were constructed by a third party (Fusion Antibodies, Belfast, UK). Briefly, the murine parental antibody (clone 9b7) was sequenced, and the consensus CDR sequences were grafted into human donor sequences *in silico*.

20

For this purpose, a number of human framework sequences (see search procedure below) were used as acceptor frameworks for the CDR sequences. These acceptor sequences have all come from mature Human IgG from a human source and not from phage display or other technologies. The generated humanized variants from the Antibody 9b7 sequences are combinations of light and heavy chains, referred to as Ab 980.2 LCXHCX (Light chain X, Heavy chain X), except that LC0HC0 refers to the chimeric antibody in which the variable domains of the original murine antibody is fused to the same human IgG constant regions as used in the humanized antibodies. The mature humanized antibodies are complete IgG molecules of the IgG1 Kappa type.

25

30

For the heavy chain, online databases of Human IgG sequences were searched for comparison to the murine VH domain using BLAST search algorithms, and candidate human variable domains selected from the top 200 BLAST results. These were reduced to four candidates based on a combination of framework homology, maintaining key framework residues and canonical loop structure.

35

For the light chain, online databases of Human IgK sequences were searched for comparison to the murine VL domain using BLAST search algorithms, and candidate human variable domains selected from the top 200 BLAST results. These were reduced to four candidates based on a combination of framework homology, maintaining key framework residues and canonical loop structure.

Altogether, DNA sequences encoding 4 humanized light chains and 4 humanized heavy chains were thus selected. All of the resulting 16 light- and heavy chain combinations were used for protein expression in CHO cells. To enable protein expression, each of the Variable Light Chain domains was positioned in-frame with a human IgK isotype constant domain sequence, while each of the Variable Heavy Chain domains was positioned in-frame with a human IgG1 isotype constant domain sequence. The chimeric antibody, LC0HC0, in which the variable domains of the murine protein were fused to the same human IgG constant regions, was expressed for comparison.

For protein expression (performed by a third party (Fusion Antibodies, Belfast, UK)), a mammalian expression vector encoding each variant was transfected into CHO cells and batch cultures of each variant grown for up to seven days. The expressed antibodies were then subsequently purified from cell culture supernatant via affinity chromatography. The concentration and purity were determined for the purified antibody products.

The obtained sequences were cloned into the mammalian transient expression plasmid pD2610-v13 (ATUM). The humanized antibody variants were expressed using a CHO based transient expression system and the resulting antibody containing cell culture supernatants were clarified by centrifugation and filtration. The humanized variants were then purified (using state-of-the-art AKTA chromatography equipment) from cell culture supernatants via affinity chromatography. Purified antibodies were dialysed/buffer exchanged into phosphate buffered saline solution. The purity of the antibody was determined to be >95%, as judged by Sodium Dodecyl Sulphate Polyacrylamide gels

Among the resulting 16 humanized antibodies, the combination designated LC4HC3 was selected for further study based on favorable protein expression yields and antigen

binding properties. Another humanized antibody designated LC3HC3 was selected for comparison with LC4HC3 of key parameters such as manufacturability, internalization and *in vivo* efficacy.

5 *SPR analyses for determination of antibody-ligand affinity*

Once suitable antibodies are obtained, they may be tested for antigen specificity, for example by surface plasmon resonance (SPR) or ELISA. When a soluble recombinant protein consisting of the three N-terminal domains of uPARAP (CysR, FN-II and CTLD-1) is immobilized in a BIAcore setup, mAb 9b7 binds to this construct.

10

SPR analyses were performed for determination of the affinity of the obtained antibodies towards uPARAP. These analyses were performed using a Biacore 2000 instrument (Biaffin GmbH, Kassel, Germany) using a CM5 sensor chip with an anti-human Fc capture surface for antibody binding. The analysis temperature was set at 25 °C. Binding of antibody onto this surface was followed by passing soluble full-length uPARAP over the chip, and the resulting association and dissociation rates were derived from the resulting binding curves. For kinetic interaction analyses, a flowrate of 30 µL/min was used and the analysis buffer consisted of 10 mM HEPES pH 7.4, 150 mM NaCl, 3 mM EDTA, 0.05% Tween 20.

20

Preparation and evaluation of antibody-drug conjugates (ADCs)

ADCs used for these studies were generated using a well-established conjugation approach. In brief, targeting antibodies were subjected to conjugation to a “vedotin” type of payload (MC-VC-PABC-MMAE) by mild reduction of interchain disulphides, followed by conjugation to a surplus of the payload via the maleimide group to a moderate average drug-to-antibody ratio (DAR) of around 4. ADCs were then purified using PD-10 desalting columns (GE Healthcare).

25

Cell lines

The U937 cell line was obtained from ATCC, and maintained in RPMI, 10% fetal bovine serum, 1% penicillin/streptomycin, in a 37 degrees Celsius incubator in a 5% CO₂ atmosphere.

30

35

In vitro cytotoxicity of ADCs - Cell viability assay

U937 cells were seeded at low density (20% confluence, 2x10³ cells per well) in a flat-bottom 96 well plate in 90µL of medium and incubated overnight. The next day, MMAE-based ADCs of the LC4HC3 and LC0HC0 antibodies, comparably synthesized using the method described above, were prepared as a serial dilution (1:4) in PBS and added in volumes of 10µL to each well, with a final maximum ADC concentration of 0.1 µg/mL ADC (mAb component). Cells were incubated for 96 hours, before 12µL of CellTiter 96 Aqueous One Solution Cell Proliferation Assay (MTS, Promega) was added, and incubated for an appropriate time for formation of color (around 60 minutes). The plates were then read at 490nm, with background subtraction at 630nm, using a plate reader, to yield the resulting viability estimates. Cells treated with PBS only were used as a nontreated control, the viability of which the ADC treated wells were normalized to.

Results*Manufacturability and expression of LC4HC3 and LC3HC3:*

The humanized antibodies designated as LC4HC3 and LC3HC3 were expressed in CHO cells and purified as described above. The same procedure was implemented for both antibodies. Results are summarized below in Table 1, clearly showing that the LC4HC3 can be produced in significantly higher quantities at sufficient purity:

Table 1 - manufacturability data for humanized antibodies LC3HC3 and LC4HC3

Antibody ID	Conc. (mg/ml)	Vol.(ml)	Total (mg)	Estimated purity (%)
LC4HC3	3.69	3.02	11.14	>95%
LC3HC3	2.42	3.06	7.41	>95%

SPR analyses:

LC4HC3 and LC0HC0 were analyzed by SPR as described in Materials and Methods above. In particular, the binding kinetics of LC4HC3 were compared with those of LC0HC0 (Table 2). As evident from these analyses, the lower K_D for the antibody LC4HC3 indicates an approx. 1.7-fold higher ligand affinity than the parental antibody, LC0HC0.

Table 2 - result overview from kinetic interaction analysis based on SPR measurements

Measurement	Kinetic global fit (Langmuir 1:1)				
	k_a (M ⁻¹ s ⁻¹)	k_d (s ⁻¹)	K_D (M)	R_{max}	% active ligand
LC0HC0	6.23×10^4	5.33×10^{-5}	8.6×10^{-10}	35.9 RU	81 %
LC4HC3	8.13×10^4	4.04×10^{-5}	5.0×10^{-10}	36.6 RU	123 %

ADC in vitro potency analysis:

- 5 MMAE-containing ADCs including either of the antibodies LC4HC3 and LC0HC0 were prepared as described above. The *in vitro* cytotoxicity of these ADCs was tested against uPARAP-positive U937 cells using concentration series of the ADCs (Fig. 1). It is evident that the amount of ADC needed for cell eradication is lower for the LC4HC3-based than for the LC0HC0-based ADC, as the viability curves resulting from treatment with LC4HC3-vc-MMAE are shifted several fold towards lower concentration, compared to the curve resulting from treatment with LC0HC0-vc-MMAE.

Conclusion

- 15 A humanized antibody, 980.2 LC4HC3, has been developed from the murine monoclonal antibody, mAb 9b7. The properties of this novel antibody can be compared directly with those resulting from the parental variable sequences by comparison with the chimeric antibody, 980.2 LC0HC0, in which the entire murine variable sequences are retained in an otherwise human IgG setting. This comparison reveals that, 1) humanized 980.2 LC4HC3 has a higher ligand affinity than 980.2 LC0HC0, and 2) an ADC based on 980.2 LC4HC3 is more efficient in terms of cytotoxicity than an otherwise equivalent ADC based on 980.2 LC0HC0.

Example 2: internalization of humanized variants of murine 9b7 antibody, LC3HC3 and LC4HC3

25

Materials and methods

Antibody labeling

- 30 Iodogen (Thermo Fischer) was dissolved at 120 µg/ml in chloroform, and used to coat the bottom of glass tubes by evaporation. In coated tubes, 200 µg/ml of humanized antibody (either LC3HC3 or LC4HC3) reacted with 588 ng/ml I-125 (Perkin Elmer) in a

0.1 M TRIS buffer at pH 7.6 for 10 minutes. The reaction was stopped by addition of a nine-fold excess of 0.1 M Tris pH 8.1 buffer containing 0.01% Tween-80. Non-bound iodine was separated from collagen over a PD-10 column, labeled antibody was eluted in a 0.1 M Tris/HCl buffer with pH 8.1, 0.01 % Tween-80. Assuming all antibody is
5 eluted in this buffer leads to a concentration of 8 µg/ml. The integrity and radioactivity of the labeled collagen was routinely confirmed by running it on SDS-PAGE, followed by Coomassie staining and phosphorimaging.

Cell culture and antibody internalization procedure

10 SAOS-2 osteosarcoma cells (Finsenlab; viability 98.7%, density of 1.07×10^6 /ml) were diluted to 1×10^5 /ml and 1 ml per 24-well was seeded for experiments. Cells were allowed to adhere overnight. At least 30 minutes prior to the addition of radiolabeled antibodies the medium was replaced by internalization medium, consisting of DMEM/F12 with 1,5% FBS and 20 mM HEPES. Internalization medium without cells
15 was seeded in separate wells as controls. It is assumed that radioactivity from these samples represents the amount of radiolabeled protein that sticks to plastic and is retrieved upon trypsin treatment. These measurements could be considered "baseline levels" and could be subtracted from measurements in samples that did contain cells. 5 µl of LC4HC3 or LC3HC3, presumed to be slightly less than 40 ng based on
20 assumptions mentioned above, was added to each well. After 1 hour or 4 hours, media was removed by suction and the cells were washed three times with 500 µl ice cold PBS. 500 µl of Trypsin-EDTA with 50 µg/ml proteinase K was added to each well for 2 minutes. Cells were harvested, transferred to Eppendorf tubes and spun at 1000g, 4°C, for 1 minute. Supernatants (containing cell-bound antibodies) and pellets were
25 collected separately and analyzed on a gamma counter. 2 µl of labeled antibody stock was analyzed simultaneously to assess labeling efficiency.

Results

30 The results presented in Fig. 2 clearly illustrate that the humanized antibody LC4HC3 is internalized not only significantly faster, but also to a larger extent than the humanized antibody LC3HC3.

Conclusion

35 Humanized antibody LC4HC3 was internalized to the largest extent by SAOS-2 osteosarcoma cells, in a time-dependent manner. LC3HC3 was also internalized, but to

a far less extent, and not as quickly as LC4HC3. The two referenced antibodies comprise the same heavy chain, and the difference in internalization can be attributed solely to the difference in amino acid sequence of the light chain.

5 **Example 3: *in vivo* efficacy of ADCs based on humanized murine 9b7 antibodies LC3HC3 and LC4HC3**

Materials and methods

10 *Cell culture and preparation*

U937 cells (as described above) were passaged according to standard procedures until enough cells for this experiment were acquired. Cells were spun down at 150 g for 5 min and washed 3 times in cold PBS (Gibco). The cell concentration was adjusted to 3.6×10^6 cells/ml. This translates to approximately 3 million live cells per 100 μ l, which is
15 the intended inoculation volume.

Xenograft tumor inoculation

Recipient CB17 mice were anesthetized with Zoletil (AEM), Viscotears eye drops were applied, and earmarks were made. The right flank was shaved and disinfected with 70
20 % ethanol. A 25G needle was used to inject 100 μ l of re-suspended U937 cells into the subcutaneous space (no incision or suture necessary). The mice were allowed to recover from the anesthesia in their cages. Recovery was monitored until the mice were mobile. The mice were monitored again the next day, and tumor sizes were monitored closely until the start of treatment.
25 Treatments were initiated as soon as the tumors reached a proper size (approximately 80-150 mm³).

ADC treatment and monitoring

Vedotin-type (MMAE) ADCs comprising the LC3HC3 or LC4HC3 humanized antibodies
30 were prepared as previously described above. The mice were divided into groups, with 3-5 animals per group (N = 3-5), the groups differing by the employed ADC or dose administered of said ADC. One cohort of mice was tested with the LC3HC3 ADC in groups receiving concentrations of 2, 4 or 6 mg/kg and another cohort was tested with the LC4HC3 ADC in groups receiving the same range of concentrations.

For each group, mice were administered a controlled amount of ADC intravenously (tail vein) once weekly, for two injections total (qd7x2), and tumor progression was closely monitored also post-treatment. Exemplary, Figs. 3a and 3b show the tumor progression in groups treated with a 4 mg/kg dose of LC4HC3 and LC3HC3 ADCs respectively.

5

The monitoring consists of checking for overall wellbeing, and measuring the width and length dimensions of the tumor with a digital caliper. All observations and measurements are noted by hand and transferred to the digital data sheets following inspection. Animals were euthanized if the tumor size exceeded 12 mm in one dimension, if the volume of the tumor (calculated as $(\text{length} \times \text{width}^2) / 2$) exceeded 1000 mm³, or if a severe impact on general wellbeing was observed. Animals were euthanized via cervical dislocation.

10

Results

U937 tumor volumes following treatment with ADCs based on LC4HC3 and LC3HC3 are found in Figs. 3a and 3b respectively. Fig. 3a shows tumor volumes for a group of four mice (N=4), each administered the LC4HC3 ADC in a 4 mg/kg once weekly for two injections total (qd7x2), and Fig. 3b shows tumor volumes for a different group of four mice (N=4), each administered the LC3HC3 ADC in a 4 mg/kg dose once weekly for two injections total (qd7x2).

20

Conclusion

As evident when comparing Figs. 3a and 3b, the treatment based on LC4HC3 ADCs completely cured all mice with no regrowth of tumor in the post-treatment period, notably in all doses tested. In contrast, the same treatment based on LC3HC3 was not able to kill all tumor cells, and in instances, aggressive tumor growth was observed in the post-treatment monitoring period.

25

The data shows that humanized antibody LC4HC3 as well as ADCs comprising said humanized antibody are potent antitumor agents with improved *in vivo* efficacy compared to another humanized antibody, LC3HC3. The two referenced antibodies comprise the same heavy chain, and the difference in efficacy can be attributed solely to the variations in amino acid sequence of the light chain.

30

35

Sequence overview

SEQ ID NO	Sequence	Comment
1	EIVMTQSPDSLAVSLGERATINCKASQNVDTYVWYQQKPGQPPQPLIYSASSRFSGVDPDRFSGSGSGTDFTLTISSLQAEDVAIYYCQQYHNSPLTFGGGKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPRFAKVKWVDNALQSGNSQESVTEQDSKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSPVTKSFNRGEC	Complete light chain sequence (LC4) of humanised LC4HC3
2	MVSSAQFLGLLLLCFQGTRCEIVMTQSPDSLAVSLGERATINCKASQNVDTYVWYQQKPGQPPQPLIYSASSRFSGVDPDRFSGSGSGTDFTLTISSLQAEDVAIYYCQQYHNSPLTFGGGKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPRFAKVKWVDNALQSGNSQESVTEQDSKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSPVTKSFNRGEC	Complete light chain sequence (LC4) of humanised LC4HC3 in combination with signal peptide used in CHO cell expression system; Signal peptide underlined
3	EIVMTQSPDSLAVSLGERATINCKASQNVDTYVWYQQKPGQPPQPLIYSASSRFSGVDPDRFSGSGSGTDFTLTISSLQAEDVAIYYCQQYHNSPLTFGGGKVEIK	Light chain (LC4) variable region of humanised LC4HC3
4	QVQLVQSGAEVKKPGASVKVSCKASGYIFIDYGMHWVRQAPGQRLEWMGSINTKSGVSTYAAEFKGRVTIYSDTSASTAYMELSSLRSEDYAVYFCARPPYYSQYGSYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTQSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWE	Complete heavy chain sequence (HC3) of humanised LC4HC3 and LC3HC3

	SNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK	
5	<u>MGWTLVFLFLLSVTAGVHSQVQLVQSGAEVKKPGASVK</u> VSCKASGYIFIDYGMHWVRQAPGQRLEWMGSINTKSGV STYAAEFKGRVTIYSDTSASTAYMELSSLRSEDNAVYFC ARPPYYSQYGSYWGQGLTVTVSSASTKGPSVFPLAPSS KSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTF PAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKHTCTPPCPAPELLGGPSVFLFPPKPK DTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHN AKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVS NKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQV SLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSD GSFFLYSKLTVDKSRWQQGNVF SCSVMHEALHNHYTQKSLSLSPGK	Complete heavy chain sequence (HC3) of humanised LC4HC3 and LC3HC3 in combination with signal peptide used in CHO cell expression system; Signal peptide underlined
6	QVQLVQSGAEVKKPGASVKVSCKASGYIFIDYGMHWVR QAPGQRLEWMGSINTKSGVSTYAAEFKGRVTIYSDTSA STAYMELSSLRSEDNAVYFCARPPYYSQYGSYWGQGL TVTVSS	Heavy chain (HC3) variable region of humanised LC4HC3 and LC3HC3
7	DIVMTQSQKFMSTSVGDRVSVTCKASQNVDTYVWYQ QKPGQSPKPLIYSASSRFSGVPDRFTGTGSGTDFTLTIN NVQSEDLAEYFCQQYHNSPLTFGGGTKLEIKRTVAAPSV FIFPPSDEQLKSGTASVCLLNNFYPREAKVQWKVDNAL QSGNSQESVTEQDSKSTYLSSTLTLSKADYEKHKVY ACEVTHQGLSPVTKSFNRGEC	Complete light chain sequence (LC0) of chimeric LC0HC0
8	DIVMTQSQKFMSTSVGDRVSVTCKASQNVDTYVWYQ QKPGQSPKPLIYSASSRFSGVPDRFTGTGSGTDFTLTIN NVQSEDLAEYFCQQYHNSPLTFGGGTKLEIK	Light chain (LC0) variable region of chimeric LC0HC0

9	QVHLVQSGPELKKPGETVKISCKASGYIFIDYGMHWVKQ APGKGLKWMGSINTKSGVSTYAAEFKGRFAFSLETSAS TAYLQINNLIKNEEDATYFCARPPYYSQYGSYWGQGLV TVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPE PVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPS SSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHCPCP PAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSH EDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVL TVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPRE PQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESN GQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNV FSCSVMHEALHNHYTQKSLSLSPGK	Complete heavy chain sequence (HC0) of chimeric LC0HC0
10	QVHLVQSGPELKKPGETVKISCKASGYIFIDYGMHWVKQ APGKGLKWMGSINTKSGVSTYAAEFKGRFAFSLETSAS TAYLQINNLIKNEEDATYFCARPPYYSQYGSYWGQGLV TVSA	Heavy chain (HC0) variable region of chimeric LC0HC0
11	ATGGTCAGCTCTGCTCAATTTCTCGGACTCCTTCTTCT GTGCTTTCAAGGAACACGCTGCGAGATCGTGATGACT CAGTCCCCGGACTCACTGGCAGTGTCTTGGGCGAA AGAGCCACCATCAACTGTAAAGCCAGCCAGAACGTGG ACACCTACGTGGTCTGGTACCAGCAGAAGCCTGGACA GCCACCGCAGCCGTTGATCTACTCGGCCTCATCAAGG TTCTCCGGGGTGCCGGACCGCTTCTCCGGATCCGGC TCCGGCACCGATTTACCCTGACCATCTCCTCACTGC AAGCCGAGGACGTGGCTATCTACTATTGCCAGCAGTA CCACAACCTCCCCACTGACCTTCGGTGGCGGAACTAAG GTCGAGATTAAGCGGACCGTGGCGGCCCCCTCTGTG TTCATTTTCCCTCCCTCGGACGAACAGCTGAAGTCGG GAACAGCCTCCGTCTGTGCCTGCTCAACAACCTTCTA CCCCCGGGAAGCGAAGGTCCAGTGGAAAGTGGATAA CGCACTCCAATCGGGGAACCTCCAGGAATCCGTGACT GAGCAGGACTCGAAGGATTCCACTTACTCCCTGTCGT CCACCCTGACTCTGAGCAAGGCCGACTACGAGAAGC ATAAGGTCTACGCCTGCGAAGTGACCCACCAGGGTCT GAGCTCCCCTGTGACCAAGAGCTTTAATCGGGGCGAA TGTTGA	Polynucleoti de encoding LC4 incl. signal peptide
12	ATGGGTTGGACCCTCGTCTTTCTGTTCTTCTTTCCGT CACCGCTGGAGTGCATAGCCAGGTCCAATTGGTGCA GTCAGGCGCCGAAGTGAAAAAGCCTGGGGCGTCCGT GAAAGTGTCTGCAAGCCTCGGGCTACATCTTTATT GACTACGGAATGCACTGGGTCCGCCAGGCCCGGGC CAGAGGCTGGAGTGGATGGGATCCATTAAACACCAAGA	Polynucleoti de encoding HC3 incl. signal peptide

	GCGGAGTGTCAACTTACGCAGCCGAGTTCAAGGGAC GGGTGACCATCTATAGCGATACCTCTGCGTCGACCGC CTACATGGAATTGTCATCACTCCGGTCCGAGGACACT GCCGTGTACTTCTGCGCAAGGCCACCCTACTACTCGC AATACGGCAGCTACTGGGGCCAGGGAACACTTGTGA CCGTGTCGAGCGCGTCCACCAAGGGTCCCTCCGTGT TCCCTCTCGCGCCGTCTCAAAGTCTACCTCCGGTGG AACTGCCGCGCTCGGTTGTCTCGTGAAGGACTACTTC CCGGAGCCTGTGACTGTCTCCTGGAACCTCCGGGGCC CTCACCAGCGGAGTGCACACTTTCCCCGCCGTGCTG CAATCCTCCGGCCTGTACAGCCTGTCTCCTCCGTCTGA CTGTGCCTAGCTCCTCCCTGGGAACCCAGACCTACAT CTGCAACGTGAACCACAAGCCCTCCAACACCAAGGTC GACAAGAAGGTGAACCGAAGTCGTGCGACAAGACT CATACGTGCCCTCCTTGCCCGGCCCGGAACTGCTG GGAGGCCCATCCGTGTTCTGTTCCACCCAAGCCTA AGGATACCCTGATGATCAGCAGAACACCGGAAGTGAC CTGTGTGGTGGTGGACGTCAGCCACGAAGATCCCGA GGTCAAGTTCAATTGGTACGTGGACGGGGTGGAGGT GCACAACGCAAAGACCAAGCCCCGGGAGGAACAGTA CAACTCCACCTATCGCGTGGTGTGGTGTGCTGACGGT GCTGCACCAGGACTGGTTGAACGGAAAGGAGTATAA GTGCAAAGTGTGAACAAGGCCCTGCCCGCTCCTATC GAAAAGACCATCTCCAAGGCCAAGGGCCAGCCGCGG GAACCCCAGGTCTACACTCTCCCACCGAGCCGCGAC GAACTGACTAAGAATCAAGTGTGCTGACTTGCCTCG TCAAGGGCTTCTACCCGTCCGACATCGCCGTGGAATG GGAGAGCAACGGCCAGCCGGAACAACACTACAAGAC CACCCCTCCCGTGCTGGATTCCGACGGGTCTTCTTC CTGTACTCAAACTGACCGTGGATAAGTCCAGATGGC AGCAGGGCAATGTCTTTTCATGCTCCGTGATGCACGA GGCTCTGCATAACCACTACACCCAGAAGTCGCTGTCC CTGTCCCCGGGGAAGTGA	
13	MVSSAQFLGLLLLCFQGTRCDVVMQSPDSLAVSLGER VTINCKASQNVDTYVWWYQQKPGQSPKLLIYSASSRFSG VPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYHNSPL TFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLL NNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTY SLSSTLTLSKADYEKHKVYACEVTHQGLSPVTKSFNRG EC	Complete light chain sequence (LC3) of humanised LC3HC3

Items 1

1. An antibody which binds to uPARAP comprising:
 - 5 a. an immunoglobulin light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 3; and/or
 - b. an immunoglobulin heavy chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 6.
- 10 2. The antibody according to item 1, wherein said antibody comprises:
 - a. an immunoglobulin light chain comprising the amino acid sequence of SEQ ID NO: 1; and/or
 - b. an immunoglobulin heavy chain comprising the amino acid sequence of SEQ ID NO: 4.
- 15 3. The antibody according to any one of the preceding items, wherein said antibody comprises:
 - 20 a. an immunoglobulin light chain consisting of the amino acid sequence of SEQ ID NO: 1; and
 - b. an immunoglobulin heavy chain consisting of the amino acid sequence of SEQ ID NO: 4.
- 25 4. An antibody-drug conjugate (ADC) comprising:
 - a. the antibody according to any one of the preceding items,
 - b. an active agent, and
 - c. optionally a linker which links a) to b).
5. The antibody-drug conjugate according to item 4, wherein the active agent is selected from a therapeutic agent, a radioisotope, and a detectable label.
- 30 6. The antibody-drug conjugate according to any one of items 4 to 5, wherein the active agent is a cytotoxic agent.
- 35 7. The antibody-drug conjugate according to any one of items 4 to 6, wherein the active agent is a therapeutic agent, such as a therapeutic agent selected from the group consisting of anti-microtubule/anti-mitotic agents, DNA crosslinking agents, DNA

- alkylating agents, DNA strand scission agents, anthracyclines, antimetabolites, histone deacetylase inhibitors, kinase inhibitors, metabolism inhibitors, peptide antibiotics, immune checkpoint inhibitors, platinum-based antineoplastics, topoisomerase inhibitors, DNA or RNA polymerase inhibitors, nucleotide based agents, and cytotoxic antibiotics.
- 5
8. The antibody-drug conjugate according to any one of items 4 to 7, wherein the active agent is an anti-mitotic agent, such as selected from the group consisting of derivatives of auristatin or dolastatin such as monomethyl auristatin E (MMAE), monomethyl auristatin F (MMAF) and more, a taxane such as Paclitaxel or Docetaxel and more, a vinca alkaloid such as Vinblastine, Vincristine, Vindesine or Vinorelbine and more, a maytansinoid, Colchicine, and Podophyllotoxin.
- 10
9. The antibody-drug conjugate according to any one of items 4 to 8, wherein the active agent is monomethyl auristatin E (MMAE).
- 15
10. The antibody-drug conjugate according to any one of items 4 to 7, wherein the active agent is a DNA-crosslinking agent, such as a DNA crosslinking agent selected from cisplatin or a derivative of cisplatin such as carboplatin or oxaliplatin, mitomycin C (MMC), pyrrolobenzodiazepine, and dimeric pyrrolobenzodiazepine derivatives such as SGD-1882.
- 20
11. The antibody-drug conjugate according to any one of items 4 to 7, wherein the active agent is a DNA alkylating agent, such as a DNA alkylating agent selected from nitrogen mustards such as tris(2-chloroethyl)amine, pyridinobenzodiazepines or a pyridinobenzodiazepine derivative, indolinobenzodiazepine dimers, and Duocarmycin SA.
- 25
12. The antibody-drug conjugate according to any one of items 4 to 7, wherein the active agent is a DNA strand scission agent, such as a DNA strand scission agent selected from calicheamicin and hamiltrene.
- 30
13. The antibody-drug conjugate according to any one of items 4 to 7, wherein the active agent is an anthracycline, such as an anthracycline selected from Daunorubicin, doxorubicin, epirubicin, idarubicin, and PNU-159682.
- 35

14. The antibody-drug conjugate according to any one of items 4 to 7, wherein the active agent is an antimetabolite, such as an antimetabolite selected from folic acid antagonists such as methotrexate, purine antimetabolites such as 6-mercaptopurine or 6-thioguanine or fludarabine phosphate or pentostatin or cladribine, and pyrimidine antimetabolites such as 5-fluorouracil or 5-fluorodeoxyuridine or cytarabine or gemcitabine.
15. The antibody-drug conjugate according to any one of items 4 to 7, wherein the active agent is a histone deacetylase inhibitor, such as a histone deacetylase inhibitor selected from trichostatin A, vorinostat, belinostat, panabostat, givinostat, resminostat, abexinostat, quisinostat, rocilinostat, practinostat, CHR-3996, valproic acid, butyric acid, phenylbutyric acid, entinostat, tacedinaline, 4SC202, mocetinostat, romidepsin, nicotinamide, sirtinol, cambinol, and EX-527.
16. The antibody-drug conjugate according to any one of items 4 to 7, wherein the active agent is a kinase inhibitor, such as a kinase inhibitor selected from genistein, lavendustin C, PP1-AG1872, PP2-AG1879, SU6656, CGP77675, PD166285, imatinib, erlotinib, gefitinib, lavendustin A, cetuximab, UCS15A, herbimycin A, and radicicol.
17. The antibody-drug conjugate according to any one of items 4 to 7, wherein the active agent is a metabolism inhibitor, such as an NAMPT inhibitor selected from APO866, GMX-1777, GMX-1778 ATG-019, and OT-82.
18. The antibody-drug conjugate according to any one of items 4 to 7, wherein the active agent is an immune checkpoint inhibitor, such as a PD-1 inhibitor selected from Pembrolizumab, Nivolumab, Cemiplimab, JTX-4014, Spartalizumab, Camrelizumab, Sintilimab, Tislelizumab, Toripalimab, Dostarlimab, AMP-224 and AMP-514; or a PD-L1 inhibitor selected from Atezolizumab, Avelumab, Durvalumab, KN035, CK-301, AUNP12, CA-170 and BMS-986189.
19. The antibody-drug conjugate according to any one of items 4 to 7, wherein the active agent is a platinum-based antineoplastic, such as a platinum-based antineoplastic selected from lipoplatin, cisplatin, carboplatin, oxaliplatin, nedaplatin, picoplatin, phenanthriplatin, satraplatin, and triplatin tetranitrate.

20. The antibody-drug conjugate according to any one of items 4 to 7, wherein the active agent is a topoisomerase inhibitor, such as a topoisomerase inhibitor selected from camptothecin or derivatives thereof such as topotecan, belotecan, lurtotecan, irinotecan, SN-38, exatecan, and Dxd.

21. The antibody-drug conjugate according to any one of items 4 to 7, wherein the active agent is a DNA- or RNA-polymerase inhibitor, such as a polymerase inhibitor selected from amanitin or alpha-amanitin or derivatives thereof, actinomycin D, and aphidicolin.

22. The antibody-drug conjugate according to any one of items 4 to 21, wherein the active agent comprises a radioisotope selected from ^{60}Co , ^{89}Sr , ^{90}Y , $^{99\text{m}}\text{Tc}$, ^{131}I , ^{137}Cs , ^{153}Sm , and ^{223}Rd .

23. The antibody-drug conjugate according to any one of items 4 to 22, wherein the drug-to-antibody ratio (DAR) is between 1 and 10, such as between 2 and 8, for example between 2 and 6, such as 2 or 4.

24. The antibody-drug conjugate according to any one of items 4 to 23, wherein the antibody-drug conjugate comprises a linker selected from a cleavable and a non-cleavable linker.

25. The antibody-drug conjugate according to any one of items 4 to 24, wherein the linker is a peptide linker.

26. The antibody-drug conjugate according to any one of items 4 to 25, wherein the linker comprises or consists of a dipeptide, such as valine-citrulline (VC) or valine-alanine (VA).

27. The antibody-drug conjugate according to any one of items 4 to 26, wherein the antibody-drug conjugate further comprises a spacer, such as a spacer comprising p-aminobenzoic acid (PAB), p-aminobenzylcarbamate (PABC), p-aminobenzoyloxycabonyl, or polyethylenglycol (PEG).

28. The antibody-drug conjugate according to any one of items 4 to 27, wherein the antibody-drug conjugate further comprises an attachment group, such as an attachment group comprising or consisting of maleimide and caproic acid (MC), N-hydroxysuccinimide, reactive attachment groups directed to modified or unmodified protein-bound carbohydrate, peptide sequences that are required for enzymatic reactions, azides or alkynes or being derived from these by reaction with the antibody or a chemically or enzymatically generated derivative thereof.
29. The antibody-drug conjugate according to any one of items 4 to 28, wherein the antibody-drug conjugate comprises or consists of:
- a. the antibody as defined in item 3,
 - b. a VC linker,
 - c. an MC attachment group,
 - d. a PAB or a PABC spacer, and
 - e. MMAE as active agent.
30. The antibody-drug conjugate according to any one of items 4 to 9 and 23 to 29, wherein the antibody-drug conjugate consists of the antibody as defined in item 3 and MC-VC-PAB-MMAE.
31. The antibody-drug conjugate according to any one of items 4 to 9 and 23 to 29, wherein the antibody-drug conjugate consists of the antibody as defined in item 3 and MC-VC-PABC-MMAE.
32. A polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO: 2 and/or SEQ ID NO: 5.
33. An isolated polynucleotide which encodes the amino acid sequence of any one of SEQ ID NOs: 1, 2, 3, 4, 5 and/or 6.
34. The isolated polynucleotide according to item 33, wherein the polynucleotide comprises SEQ ID NO: 11 and/or SEQ ID NO: 12.
35. A vector comprising the polynucleotide as defined in any one of items 33 to 34.

36. The vector according to item 35, wherein the vector is a mammalian expression vector.

5 37. The vector according to any one of items 35 to 36, wherein the vector is a plasmid vector, such as a plasmid vector selected from pD2610-v13 (ATUM), pSV and the pCMV series of plasmid vectors.

10 38. The vector according to any one of items 35 to 37, wherein the vector is a viral vector, such as a viral vector selected from the group consisting of adenoviral vectors, lentiviral vectors, adeno-associated viral vectors, herpesviral vectors, vaccinia viral vectors, poxviral vectors, baculoviral vectors and oncolytic viral vectors.

15 39. A host cell comprising the polynucleotide according to items 32 to 33 and/or the vector according to any one of items 35 to 38.

20 40. The host cell according to item 39, wherein the host cell is selected from the group consisting of CHO (Chinese hamster ovary) cells, COS (CV-1 (simian) in Origin, and carrying the SV40 genetic material) cells, HEK (Human embryonic kidney) cells and HeLa (Henrietta Lacks) cells.

41. The antibody according to any one of items 1 to 3 or the antibody-drug conjugate according to any one of items 4 to 31 for use as a medicament.

25 42. A pharmaceutical composition comprising the antibody according to any one of items 1 to 3 or the antibody-drug conjugate according to any one of items 4 to 31 and a pharmaceutically acceptable buffer, diluent, carrier, adjuvant or excipient.

30 43. A method for treatment of a disease characterised by cells expressing uPARAP, said method comprising administering to a subject the antibody according to any one of items 1 to 3, the antibody-drug conjugate according to any one of items 4 to 31 or the pharmaceutical composition according to item 42.

44. The method according to item 43, wherein the disease characterised by cells expressing uPARAP is selected from cancer, a bone degradation disease such as

osteoporosis, fibrosis, and macrophage associated diseases or disorders such as atherosclerosis, arthritis or chronic inflammation.

5 45. The method according to item 44, wherein the arthritis is selected from osteoarthritis, inflammatory arthritis, rheumatoid arthritis, psoriatic arthritis, lupus, Lyme disease-induced arthritis such as Lyme arthritis, gout or pseudogout, and ankylosing spondylitis.

10 46. The method according to any of items 43 to 44, wherein the disease is cancer.

47. The method according to item 46, wherein the cancer is selected from sarcoma, glioblastoma, mesothelioma, colon cancer, prostate cancer, bone metastases from prostate cancer, breast cancer, head- and neck cancer and leukaemia.

15 48. The method according to any of items 46 to 47, wherein the cancer is a solid tumour.

49. The method according to any of items 46 to 47, wherein cancer is leukaemia, such as acute lymphoblastic leukaemia (ALL), acute myeloid leukaemia (AML), chronic lymphocytic leukaemia (CLL), and chronic myeloid leukaemia (CML).
20

50. The method according to any of items 46 to 48, wherein the cancer is glioblastoma.

25 51. The method according to any of items 46 to 48, wherein the cancer is sarcoma, such as osteosarcoma, or soft tissue sarcoma (STS).

52. The method according to item 51, wherein the soft tissue sarcoma (STS) is selected from epithelioid sarcoma, clear cell sarcoma, alveolar soft part sarcoma, extraskeletal myxoid chondrosarcoma, epithelioid hemangioendothelioma, inflammatory myofibroblastic tumor, undifferentiated embryonal sarcoma, alveolar soft part sarcoma (ASPS), angiosarcoma, chondrosarcoma, dermatofibrosarcoma protuberans (DFSP), desmoid sarcoma, Ewing's sarcoma, fibrosarcoma, myxofibrosarcoma, gastrointestinal stromal tumor (GIST), non-uterine leiomyosarcoma, uterine leiomyosarcoma, liposarcoma, malignant fibro histiocytoma
30

(MFH), malignant peripheral nerve sheath tumor (MPNST), rhabdomyosarcoma, synovial sarcoma, and/or leiomyosarcoma (LMS).

53. The method according to any one of items 46 to 52, wherein the cancer is metastatic cancer.

54. The method according to any of items 43 to 53, wherein the antibody according to any one of items 1 to 3, the antibody-drug conjugate according to any one of items 4 to 31, or the pharmaceutical composition according to items 42 is administered parenterally, for example, intravenously, intracerebroventricularly, intraarticularly, intra-arterially, intraperitoneally, intrathecally, intraventricularly, intrasternally, intracranially, intramuscularly or subcutaneously, or by infusion techniques.

55. The method according to any of items 43 to 54, wherein the antibody according to any one of items 1 to 3, the antibody-drug conjugate according to any one of items 4 to 31, or the pharmaceutical composition according to item 42 is administered intravenously.

56. The method according to any of items 43 to 55, wherein the antibody according to any one of items 1 to 3, the antibody-drug conjugate according to any one of items 4 to 31, or the pharmaceutical composition according to item 42 is administered in combination with one or more further agents, such as one or more further therapeutic agents.

57. The method according to any of items 43 to 56, wherein the cells expressing uPARAP display uPARAP overexpression.

58. The method according to any of items 43 to 57, wherein the cells expressing uPARAP are tumour cells and/or tumour associated cells.

59. The method according to any of items 43 to 58, wherein the antibody according to any one of items 1 to 3, the antibody-drug conjugate according to any one of items 4 to 31, or the pharmaceutical composition according to item 42 induces cell death and/or inhibits the growth and/or proliferation of the uPARAP expressing cells.

60. The method according to any of items 43 to 59, wherein the antibody according to any one of items 1 to 3, the antibody-drug conjugate according to any one of items 4 to 31, or the pharmaceutical composition according to item 42 induces liberation of free cytotoxin from the uPARAP expressing cells, leading to cell death and/or inhibition of the growth and/or proliferation of neighbouring cancer cells.

61. The method according to any of items 43 to 60, wherein the treatment is ameliorative or curative.

62. A method for inhibiting tumour progression in a subject, comprising administering to the subject the antibody according to any one of items 1 to 3, the antibody-drug conjugate according to any one of items 4 to 31, or the pharmaceutical composition according to item 42.

63. A method for inhibiting, lowering or eliminating metastatic capacity of an uPARAP expressing tumour in a subject, comprising administering to the subject the antibody according to any one of items 1 to 3, the antibody-drug conjugate according to any one of items 4 to 31, or the pharmaceutical composition according to item 42.

64. A kit comprising the antibody according to any one of items 1 to 3, the antibody-drug conjugate according to any one of items 4 to 31, or the pharmaceutical composition according to item 42, optionally further comprising means for administering the antibody or antibody-drug conjugate to a subject and/or instructions for use.

65. The antibody according to any one of items 1 to 3, the antibody-drug conjugate according to any one of items 4 to 31, or the pharmaceutical composition according to item 42 for use in the manufacture of a medicament for treatment of a disease characterised by cells expressing uPARAP, such as cancer.

Items 2

1. An antibody which binds to uPARAP comprising:
 - a. an immunoglobulin light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 3; and/or
 - b. an immunoglobulin heavy chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 6.
2. An antibody-drug conjugate (ADC) comprising:
 - a. the antibody according to item 1,
 - b. an active agent, and
 - c. optionally a linker which links a) to b).
3. The antibody-drug conjugate according to item 2, wherein the active agent is a therapeutic agent, such as a therapeutic agent selected from the group consisting of anti-microtubule/anti-mitotic agents, DNA crosslinking agents, DNA alkylating agents, DNA strand scission agents, anthracyclines, antimetabolites, histone deacetylase inhibitors, kinase inhibitors, metabolism inhibitors, peptide antibiotics, immune checkpoint inhibitors, platinum-based antineoplastics, topoisomerase inhibitors, DNA or RNA polymerase inhibitors, nucleotide based agents, and cytotoxic antibiotics.
4. The antibody-drug conjugate according to any one of items 2 to 3, wherein the antibody-drug conjugate comprises a linker selected from a cleavable and a non-cleavable linker.
5. The antibody-drug conjugate according to any one of items 2 to 4, wherein the antibody-drug conjugate further comprises a spacer, such as a spacer comprising p-aminobenzoic acid (PAB), p-aminobenzylcarbamate (PABC), p-aminobenzoyloxycabonyl, or polyethylenglycol (PEG).
6. The antibody-drug conjugate according to any one of items 2 to 5, wherein the antibody-drug conjugate comprises or consists of:
 - a. the antibody as defined in item 1,
 - b. a VC linker,

- c. an MC attachment group,
 - d. a PAB or a PABC spacer, and
 - e. MMAE as active agent.
- 5 7. A polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO: 2 and/or SEQ ID NO: 5.
8. An isolated polynucleotide which encodes the amino acid sequence of any one of SEQ ID NOs: 1, 2, 3, 4, 5 and/or 6.
- 10 9. The antibody according to item 1, or the antibody-drug conjugate according to any one of items 2 to 6 for use as a medicament.
- 15 10. A pharmaceutical composition comprising the antibody according to item 1, or the antibody-drug conjugate according to any one of items 2 to 6 and a pharmaceutically acceptable buffer, diluent, carrier, adjuvant or excipient.
- 20 11. The antibody according to item 1, the antibody-drug conjugate according to any one of items 2 to 6, or the pharmaceutical composition according to item 10, for use in a method of treatment of a disease characterised by cells expressing uPARAP.
- 25 12. The antibody according to item 1, the antibody-drug conjugate according to any one of items 2 to 6, or the pharmaceutical composition according to item 10 for use according to item 11, wherein the disease characterised by cells expressing uPARAP is selected from cancer, a bone degradation disease such as osteoporosis, fibrosis, and macrophage associated diseases or disorders such as atherosclerosis, arthritis or chronic inflammation.
- 30 13. The antibody according to item 1, the antibody-drug conjugate according to any one of items 2 to 6, or the pharmaceutical composition according to item 10 for use in a method of inhibiting tumour progression in a subject.
- 35 14. The antibody according to item 1, the antibody-drug conjugate according to any one of items 2 to 6, or the pharmaceutical composition according to item 10 for

use in a method of inhibiting, lowering or eliminating metastatic capacity of an uPARAP expressing tumour.

- 5 15. A kit comprising the antibody according to item 1, the antibody-drug conjugate according to any one of items 2 to 6, or the pharmaceutical composition according to item 10, optionally further comprising means for administering the antibody or antibody-drug conjugate to a subject and/or instructions for use.

Claims

1. An antibody which binds to uPARAP comprising:
- 5 a. an immunoglobulin light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 3; and
- b. an immunoglobulin heavy chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 6.
2. The antibody according to claim 1, wherein said antibody comprises:
- 10 a. an immunoglobulin light chain comprising the amino acid sequence of SEQ ID NO: 1; and
- b. an immunoglobulin heavy chain comprising the amino acid sequence of SEQ ID NO: 4.
3. The antibody according to any one of the preceding claims, wherein said antibody
- 15 comprises:
- a. an immunoglobulin light chain consisting of the amino acid sequence of SEQ ID NO: 1; and
- b. an immunoglobulin heavy chain consisting of the amino acid sequence of SEQ ID NO: 4.
- 20
4. An antibody-drug conjugate (ADC) comprising:
- a. the antibody as defined in any one of the preceding claims,
- b. an active agent, and
- c. optionally a linker which links a) to b).
- 25
5. The antibody-drug conjugate according to claim 4, wherein the active agent is selected from a therapeutic agent, a radioisotope, and a detectable label.
6. The antibody-drug conjugate according to any one of claims 4 to 5, wherein the
- 30 active agent is a cytotoxic agent.
7. The antibody-drug conjugate according to any one of claims 4 to 6, wherein the active agent is a therapeutic agent, such as a therapeutic agent selected from the group consisting of anti-microtubule/anti-mitotic agents, DNA crosslinking agents, DNA
- 35 alkylating agents, DNA strand scission agents, anthracyclines, antimetabolites, histone

deacetylase inhibitors, kinase inhibitors, metabolism inhibitors, peptide antibiotics, immune checkpoint inhibitors, platinum-based antineoplastics, topoisomerase inhibitors, DNA or RNA polymerase inhibitors, nucleotide based agents, and cytotoxic antibiotics.

5

8. The antibody-drug conjugate according to any one of claims 4 to 7, wherein the active agent is an anti-mitotic agent, such as selected from the group consisting of derivatives of auristatin or dolastatin such as monomethyl auristatin E (MMAE), monomethyl auristatin F (MMAF) and more, a taxane such as Paclitaxel or Docetaxel and more, a vinca alkaloid such as Vinblastine, Vincristine, Vindesine or Vinorelbine and more, a maytansinoid, Colchicine, and Podophyllotoxin.

10

9. The antibody-drug conjugate according to any one of claims 4 to 8, wherein the active agent is monomethyl auristatin E (MMAE).

15

10. The antibody-drug conjugate according to any one of claims 4 to 7, wherein the active agent is a DNA-crosslinking agent, such as a DNA crosslinking agent selected from cisplatin or a derivative of cisplatin such as carboplatin or oxaliplatin, mitomycin C (MMC), pyrrolobenzodiazepine, and dimeric pyrrolobenzodiazepine derivatives such as SGD-1882.

20

11. The antibody-drug conjugate according to any one of claims 4 to 7, wherein the active agent is a DNA alkylating agent, such as a DNA alkylating agent selected from nitrogen mustards such as tris(2-chloroethyl)amine, pyridinobenzodiazepines or a pyridinobenzodiazepine derivative, indolinobenzodiazepine dimers, and Duocarmycin SA.

25

12. The antibody-drug conjugate according to any one of claims 4 to 7, wherein the active agent is a DNA strand scission agent, such as a DNA strand scission agent selected from calicheamicin and hamiltroline.

30

13. The antibody-drug conjugate according to any one of claims 4 to 7, wherein the active agent is an anthracycline, such as an anthracycline selected from Daunorubicin, doxorubicin, epirubicin, idarubicin, and PNU-159682.

35

14. The antibody-drug conjugate according to any one of claims 4 to 7, wherein the active agent is an antimetabolite, such as an antimetabolite selected from folic acid antagonists such as methotrexate, purine antimetabolites such as 6-mercaptopurine or 6-thioguanine or fludarabine phosphate or pentostatin or cladribine, and pyrimidine
5 antimetabolites such as 5-fluorouracil or 5-fluorodeoxyuridine or cytarabine or gemcitabine.

15. The antibody-drug conjugate according to any one of claims 4 to 7, wherein the active agent is a histone deacetylase inhibitor, such as a histone deacetylase inhibitor
10 selected from trichostatin A, vorinostat, belinostat, panabiosat, givinostat, resminostat, abexinostat, quisinostat, rocilinostat, practinostat, CHR-3996, valproic acid, butyric acid, phenylbutyric acid, entinostat, tacedinaline, 4SC202, mocetinostat, romidepsin, nicotinamide, sirtinol, cambinol, and EX-527.

15 16. The antibody-drug conjugate according to any one of claims 4 to 7, wherein the active agent is a kinase inhibitor, such as a kinase inhibitor selected from genistein, lavendustin C, PP1-AG1872, PP2-AG1879, SU6656, CGP77675, PD166285, imatinib, erlotinib, gefitinib, lavendustin A, cetuximab, UCS15A, herbimycin A, and radicicol.

20 17. The antibody-drug conjugate according to any one of claims 4 to 7, wherein the active agent is a metabolism inhibitor, such as an NAMPT inhibitor selected from APO866, GMX-1777, GMX-1778 ATG-019, and OT-82.

25 18. The antibody-drug conjugate according to any one of claims 4 to 7, wherein the active agent is an immune checkpoint inhibitor, such as a PD-1 inhibitor selected from Pembrolizumab, Nivolumab, Cemiplimab, JTX-4014, Spartalizumab, Camrelizumab, Sintilimab, Tislelizumab, Toripalimab, Dostarlimab, AMP-224 and AMP-514; or a PD-L1 inhibitor selected from Atezolizumab, Avelumab, Durvalumab, KN035, CK-301, AUNP12, CA-170 and BMS-986189.

30 19. The antibody-drug conjugate according to any one of claims 4 to 7, wherein the active agent is a platinum-based antineoplastic, such as a platinum-based antineoplastic selected from lipoplatin, cisplatin, carboplatin, oxaliplatin, nedaplatin, picoplatin, phenanthriplatin, satraplatin, and triplatin tetranitrate.

35

20. The antibody-drug conjugate according to any one of claims 4 to 7, wherein the active agent is a topoisomerase inhibitor, such as a topoisomerase inhibitor selected from camptothecin or derivatives thereof such as topotecan, belotecan, lurtotecan, irinotecan, SN-38, exatecan, and Dxd.
- 5 21. The antibody-drug conjugate according to any one of claims 4 to 7, wherein the active agent is a DNA- or RNA-polymerase inhibitor, such as a polymerase inhibitor selected from amanitin or alpha-amanitin or derivatives thereof, actinomycin D, and aphidicolin.
- 10 22. The antibody-drug conjugate according to any one of claims 4 to 21, wherein the active agent comprises a radioisotope selected from ^{60}Co , ^{89}Sr , ^{90}Y , $^{99\text{m}}\text{Tc}$, ^{131}I , ^{137}Cs , ^{153}Sm , and ^{223}Rd .
- 15 23. The antibody-drug conjugate according to any one of claims 4 to 22, wherein the drug-to-antibody ratio (DAR) is between 1 and 10, such as between 2 and 8, for example between 2 and 6, such as 2 or 4.
- 20 24. The antibody-drug conjugate according to any one of claims 4 to 23, wherein the antibody-drug conjugate comprises a linker selected from a cleavable and a non-cleavable linker, optionally wherein the linker is a peptide linker.
- 25 25. The antibody-drug conjugate according to any one of claims 4 to 24, wherein the linker comprises or consists of a dipeptide, such as valine-citrulline (VC) or valine-alanine (VA).
- 30 26. The antibody-drug conjugate according to any one of claims 4 to 25, wherein the antibody-drug conjugate further comprises a spacer, such as a spacer comprising p-aminobenzoic acid (PAB), p-aminobenzylcarbamate (PABC), p-aminobenzoyloxycarbonyl, or polyethylenglycol (PEG).
- 35 27. The antibody-drug conjugate according to any one of claims 4 to 26, wherein the antibody-drug conjugate further comprises an attachment group, such as an attachment group comprising or consisting of maleimide and caproic acid (MC), N-hydroxysuccinimide, reactive attachment groups directed to modified or unmodified

protein-bound carbohydrate, peptide sequences that are required for enzymatic reactions, azides or alkynes or being derived from these by reaction with the antibody or a chemically or enzymatically generated derivative thereof.

- 5 28. The antibody-drug conjugate according to any one of claims 4 to 9 and 23 to 27,
wherein the antibody-drug conjugate comprises or consists of:
- a. the antibody as defined in claim 3,
 - b. a VC linker,
 - c. an MC attachment group,
 - 10 d. a PAB or a PABC spacer, and
 - e. MMAE as active agent.
29. The antibody-drug conjugate according to any one of claims 4 to 9 and 23 to 28,
wherein the antibody-drug conjugate consists of the antibody as defined in claim 3 and
15 MC-VC-PAB-MMAE.
30. The antibody-drug conjugate according to any one of claims 4 to 9 and 23 to 29,
wherein the antibody-drug conjugate consists of the antibody as defined in claim 3 and
MC-VC-PABC-MMAE.
- 20 31. A polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO:
2, optionally further comprising the amino acid sequence of SEQ ID NO: 5.
32. An isolated polynucleotide which encodes the amino acid sequence of any one of
25 SEQ ID NOs: 1, 2, or 3, optionally wherein the polynucleotide further encodes the
amino acid sequence of any one of 4, 5 or 6.
33. The isolated polynucleotide according to claim 33, wherein the polynucleotide
comprises SEQ ID NO: 11, optionally further comprising SEQ ID NO: 12.
- 30 34. A vector comprising the polynucleotide as defined in any one of claims 32 to 33.
35. A host cell comprising the polynucleotide as defined in any one of as defined in any
one of claims 32 or 33 and/or the vector as defined in claim 34.
- 35

36. The antibody according to any one of claims 1 to 3 or the antibody-drug conjugate according to any one of claims 4 to 30 for use as a medicament.

5 37. A pharmaceutical composition comprising the antibody according to any one of claims 1 to 3 or the antibody-drug conjugate according to any one of claims 4 to 30 and a pharmaceutically acceptable buffer, diluent, carrier, adjuvant or excipient.

10 38. The antibody according to any one of claims 1 to 3, the antibody-drug conjugate according to any one of claims 4 to 30 or the pharmaceutical composition according to claim 37 for use in the treatment of a disease characterised by cells expressing uPARAP.

15 39. The antibody, antibody-drug conjugate or composition for use according to claim 38, wherein the disease characterised by cells expressing uPARAP is selected from cancer, a bone degradation disease such as osteoporosis, fibrosis, and macrophage associated diseases or disorders such as atherosclerosis, arthritis or chronic inflammation.

20 40. The antibody, antibody-drug conjugate or composition for use according to claim 39, wherein the arthritis is selected from osteoarthritis, inflammatory arthritis, rheumatoid arthritis, psoriatic arthritis, lupus, Lyme disease-induced arthritis such as Lyme arthritis, gout or pseudogout, and ankylosing spondylitis.

25 41. The antibody, antibody-drug conjugate or composition for use according to any one of claims 38 to 39, wherein the disease is cancer, such as wherein the cancer is selected from sarcoma, glioblastoma, mesothelioma, colon cancer, prostate cancer, bone metastases from prostate cancer, breast cancer, head- and neck cancer and leukaemia.

30 42. The antibody, antibody-drug conjugate or composition for use according to claim 41, wherein the cancer is a solid tumour.

43. The antibody, antibody-drug conjugate or composition for use according to claim 41, wherein cancer is leukaemia, such as acute lymphoblastic leukaemia (ALL), acute

myeloid leukaemia (AML), chronic lymphocytic leukaemia (CLL), and chronic myeloid leukaemia (CML).

5 44. The antibody, antibody-drug conjugate or composition for use according to any one of claims 41 to 42, wherein the cancer is glioblastoma.

45. The antibody, antibody-drug conjugate or composition for use according to any one of claims 41 to 42, wherein the cancer is sarcoma, such as osteosarcoma, or soft tissue sarcoma (STS).

10

46. The antibody, antibody-drug conjugate or composition for use according to claim 45, wherein the soft tissue sarcoma (STS) is selected from epithelioid sarcoma, clear cell sarcoma, alveolar soft part sarcoma, extraskeletal myxoid chondrosarcoma, epithelioid hemangioendothelioma, inflammatory myofibroblastic tumor, undifferentiated embryonal sarcoma, alveolar soft part sarcoma (ASPS), angiosarcoma, chondrosarcoma, dermatofibrosarcoma protuberans (DFSP), desmoid sarcoma, Ewing's sarcoma, fibrosarcoma, myxofibrosarcoma, gastrointestinal stromal tumor (GIST), non-uterine leiomyosarcoma, uterine leiomyosarcoma, liposarcoma, malignant fibro histiocytoma (MFH), malignant peripheral nerve sheath tumor (MPNST), rhabdomyosarcoma, synovial sarcoma, and/or leiomyosarcoma (LMS).

20

47. The antibody, antibody-drug conjugate or composition for use according to any one of claims 41 to 46, wherein the cancer is metastatic cancer.

25 48. The antibody, antibody-drug conjugate or composition for use according to any one of claims 38 to 47, wherein administration is parenteral, for example, intravenously, intracerebroventricularly, intraarticularly, intra-arterially, intraperitoneally, intrathecally, intraventricularly, intrasternally, intracranially, intramuscularly or subcutaneously, or by infusion techniques.

30

49. The antibody, antibody-drug conjugate or composition for use according to any one of claims 38 to 48, wherein administration is intravenous.

50. The antibody, antibody-drug conjugate or composition for use according to any one of claims 38 to 49, wherein the antibody, antibody-drug conjugate or composition is

35

administered in combination with one or more further agents, such as one or more further therapeutic agents.

51. The antibody, antibody-drug conjugate or composition for use according to any one
5 of claims 38 to 50, wherein the cells expressing uPARAP display uPARAP overexpression, optionally wherein the cells expressing uPARAP are tumour cells and/or tumour associated cells.

52. The antibody, antibody-drug conjugate or composition for use according to any one
10 of claims 38 to 51, wherein the antibody, antibody-drug conjugate or composition induces cell death and/or inhibits the growth and/or proliferation of the uPARAP expressing cells.

53. The antibody, antibody-drug conjugate or composition for use according to any one
15 of claims 38 to 52, wherein the antibody, antibody-drug conjugate or composition induces liberation of free cytotoxin from the uPARAP expressing cells, leading to cell death and/or inhibition of the growth and/or proliferation of neighbouring cancer cells.

54. The antibody, antibody-drug conjugate or composition for use according to any one
20 of claims 38 to 53, wherein the treatment is ameliorative or curative.

55. The antibody according to any one of claims 1 to 3, the antibody-drug conjugate according to any one of claims 4 to 30 or the pharmaceutical composition according to claim 37 for use in a method for inhibiting tumour progression in a subject.

25 56. The antibody according to any one of claims 1 to 3, the antibody-drug conjugate according to any one of claims 4 to 30 or the pharmaceutical composition according to claim 37 for use in a method for inhibiting, lowering or eliminating metastatic capacity of an uPARAP expressing tumour in a subject.

30 57. A kit comprising the antibody according to any one of claims 1 to 3, the antibody-drug conjugate according to any one of claims 4 to 30, or the pharmaceutical composition according to claim 37, optionally further comprising means for administering the antibody or antibody-drug conjugate to a subject and/or instructions
35 for use.

58. The antibody according to any one of claims 1 to 3, the antibody-drug conjugate according to any one of claims 4 to 30, or the pharmaceutical composition according to claim 37 for use in the manufacture of a medicament for treatment of a disease
- 5 characterised by cells expressing uPARAP, such as cancer.